WO2015082376A2 - Utilisation d'inhibiteurs de pi3k - Google Patents

Utilisation d'inhibiteurs de pi3k Download PDF

Info

Publication number
WO2015082376A2
WO2015082376A2 PCT/EP2014/076051 EP2014076051W WO2015082376A2 WO 2015082376 A2 WO2015082376 A2 WO 2015082376A2 EP 2014076051 W EP2014076051 W EP 2014076051W WO 2015082376 A2 WO2015082376 A2 WO 2015082376A2
Authority
WO
WIPO (PCT)
Prior art keywords
alkyl
dihydroimidazo
quinazolin
methoxy
carboxamide
Prior art date
Application number
PCT/EP2014/076051
Other languages
English (en)
Other versions
WO2015082376A3 (fr
Inventor
Liu NINGSHU
Arne Scholz
Andrea HÄGEBARTH
Original Assignee
Bayer Pharma Aktiengesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma Aktiengesellschaft filed Critical Bayer Pharma Aktiengesellschaft
Publication of WO2015082376A2 publication Critical patent/WO2015082376A2/fr
Publication of WO2015082376A3 publication Critical patent/WO2015082376A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Definitions

  • the present invention relates to the use of a compound of general formula (I),
  • R 1 represents -(CH2)n-(CHR 4 )-(CH 2 )m
  • X represents N or C-R 6 .
  • X' represents O, S, NH, N-R 6 , N or C-R 6 ,
  • R 3 is methyl
  • R 4 is hydroxy
  • R 5 and R 5' are the same or different and are, independently of each other, a hydrogen atom, or a Ci-Ce-alkyl, Ca-Ce-cycloalkyl-Ci-Ce-alkyl, or Ci-Ce-alkoxy- Ci-Ce-alkyl,
  • R 5 and R 5' taken together with the nitrogen atom to which they are bound, represent a 3- to 7-membered nitrogen containing heterocyclic ring optionally containing at least one additional heteroatom selected from oxygen, nitrogen or sulfur and which may be optionally substituted with 1 or more R 6' groups ; each occurrence of R 6 may be the same or different and is independently a hydrogen atom, a halogen atom, Ci-Ce-alkyl, C2-C6-alkenyl, C2-C6-alkynyl, C3- Ce-cycloalkyl, Ca-Ce-cycloalkyl-Ci-Ce-alkyl, aryl, aryl-Ci -Ce-alkyl, heteroaryl, heteroaryl-Ci -Ce-alkyl, 3- to 8-membered heterocyclic ring, 3- to 8-membered heterocyclyl-O-Ce-alkyl, -Ci-Ce-alkyl-OR 7 , -
  • * represents the point of attachment with the rest of the structure of general formula (I), as a sole active agent, or a stereoisomer, a tautomer, an N-oxide, a hydrate, a solvate, or a salt thereof, in particular a physiologically acceptable salt, for the preparation of a medicament for the treatment or prophylaxis of cancer, particularly breast cancer, prostate cancer, multiple myeloma, hepatocyte carcinoma, lung cancer, in particular non-small cell lung carcinoma, colorectal cancer, melanoma, pancreatic cancer and/or metastases thereof.
  • cancer particularly breast cancer, prostate cancer, multiple myeloma, hepatocyte carcinoma, lung cancer, in particular non-small cell lung carcinoma, colorectal cancer, melanoma, pancreatic cancer and/or metastases thereof.
  • Another aspect of the present invention relates to the use of the compounds of formula (I) as described herein for the preparation of a medicament for the treatment or prophylaxis of breast cancer or prostate cancer and/or metastases thereof.
  • the metastases are bone metastases.
  • the present invention further relates to a combination of
  • anti-angiogenesis anti-hyper-proliferative, anti-inflammatory, analgesic, immunoregulatory, diuretic, antiarrhytmic, anti-hypercholsterolemia, anti- dyslipidemia, anti-diabetic or antiviral agents, and/or admixtures or combinations thereof.
  • Another aspect of the invention relates to a pharmaceutical composition which comprises a combination as described supra. Yet another aspect of the invention relates to the use of a combination or of a pharmaceutical composition as described supra
  • a cancer for the preparation of a medicament for the treatment or prophylaxis of a cancer, particularly breast cancer, prostate cancer, multiple myeloma, hepatocyte carcinoma, lung cancer, in particular non-small cell lung carcinoma, colorectal cancer, melanoma, pancreatic cancer and/or metastases thereof.
  • Another aspect of the present invention relates to a method of treatment or prophylaxis of a cancer, particularly multiple myeloma, hepatocyte carcinoma, lung cancer, in particular non-small cell lung carcinoma, colorectal cancer, melanoma, pancreatic cancer, prostate cancer, breast cancer and/or metastases thereof, in a subject, comprising administering to said subject a therapeutically effective amount of a compound as described herein.
  • kits comprising a combination of :
  • anti-angiogenesis anti-hyper-proliferative, antiinflammatory, analgesic, immunoregulatory, diuretic, antiarrhytmic, anti-hypercholsterolemia, anti- dyslipidemia, anti-diabetic or antiviral agents, and/or admixtures or combinations thereof, in which optionally both or either of said compounds as described herein and further active agents are in the form of a pharmaceutical formulation which is ready for use to be administered simultaneously, concurrently, separately or sequentially.
  • Cancer is the second most prevalent cause of death in the United States, causing 450,000 deaths per year. While substantial progress has been made in identifying some of the likely environmental and hereditary causes of cancer, there is a need for additional therapeutic modalities that target cancer and related diseases. In particular there is a need for therapeutic methods for treating diseases associated with dysregulated growth / proliferation.
  • Cancer is a complex disease arising after a selection process for cells with acquired functional capabilities like enhanced survival / resistance towards apoptosis and a limitless proliferative potential. Thus, it is preferred to develop drugs for cancer therapy addressing distinct features of established tumors.
  • the PI3K/AKT/mTOR pathway which is constitutively activated in many types of cancers, is one of the prominent pathway that promote tumor cell survival. Initial activation of the PI3K/AKT/mTOR pathway occurs at the cell membrane, where the signal for pathway activation is propagated through class I A PI3K. Activation of PI3K can occur through tyrosine kinase growth factor receptors (e.g.
  • PDGF-R platelet- derived growth factor receptor
  • EGFR human epidermal growth factor 1 /2/3 receptor
  • IGF-1 R insulin-like growth factor 1 receptor
  • ILK integrin-linked kinase
  • CaMKK Ca2+/calmodul independent kinase kinase
  • DNA-PK nuclear DNA-dependent protein kinase
  • Ras Ras
  • PI3K Once PI3K is activated, it catalyzes phosphorylation of the D-3 position on phosphoinositides to generate the biologically-active phosphatidylinositol-3,4,5- triphosphate [PI(3,4,5)P3, PIP3] and phosphatidylinositol-3,4-bisphosphate [PI(3,4)P 2 , PIP2].
  • PIPs binds to the pleckstrin homology (PH) domains of phosphoinositide-dependent kinase 1 (PDK-1 ), AKT, and other PH-domain containing proteins, such as Rho and PLC. As the consequence of binding to PIP3, the proteins are translocated to the cell membrane and are subsequently activated.
  • PH pleckstrin homology
  • tumour suppressor PTEN phosphatase and tensin homolog deleted on chromosome 10. antagonizes PI3K by dephosphorylating PIP3, thereby preventing translocation and activation of PDK1 , AKT and other signaling proteins.
  • AKT is the major effecter of PI3K, which elicits a broad range of downstream signaling events. It recognizes and phosphorylates the consensus sequence RXRXX(S/T) when surrounded by hydrophobic residues. As this sequence is present in many proteins, about 50 AKT substrates have been identified and validated. 3 ' 4 These substrates control key cellular processes such as apoptosis, cell cycle progression, transcription, and translation, stress adaptation, metabolism, and metastasis of tumor cells. For instance, AKT phosphorylates the FOXO subfamily of forkhead family transcription factors, which inhibits transcription of several pro-apoptotic genes, e.g. Fas-L, IGFBP1 and Bim.
  • AKT can directly regulate apoptosis by phosphorylating and inactivating pro-apoptotic proteins such as Bad, which control the release of cytochrome c from mitochondria, and apoptosis signal-regulating kinase-1 , a mitogen-activated protein kinase kinase involved in stress-induced and cytokine- induced cell death. 7
  • AKT can phosphorylate ⁇ kinase, which indirectly increases the activity of nuclear factor ⁇ and stimulates the transcription of pro-survival genes.
  • AKT cyclin dependent kinase inhibitors
  • MDM2 mouse double minute 2
  • AKT has also an important function in the control of the G2/M transition by e.g. phosphorylation of Myt1 and FOXO3a.
  • AKT serine/threonine kinase mTOR
  • AKT can directly phosphorylate and activate mTOR, as well as cause indirect activation of mTOR by phosphorylating and inactivating TSC2 (tuberous sclerosis complex 2, also called tuberin), which normally inhibits mTOR through the GTP-binding protein Rheb (Ras homolog enriched in brain).
  • TSC2 tuberous sclerosis complex 2, also called tuberin
  • Rheb GTP-binding protein
  • mTOR exists in two complexes: the TORC1 complex, in which mTOR is bound to Raptor, and the TORC2 complex, in which mTOR is bound to Rictor. 12
  • mTOR phosphorylates its downstream effectors S6 kinase (S6K1 ) and 4EBP-1 .
  • S6K1 can then phosphorylate its substrate, a ribosomal protein called S6.
  • 4EBP-1 when phosphorylated cannot bind effectively to its binding partner, elF4E.
  • the cumulative effect is to increase protein translation, especially of highly structured, capped mRNA species.
  • mTOR is generally considered a downstream substrate of AKT
  • mTOR in complex with Rictor can also phosphorylate AKT at S473, thereby providing a level of positive feedback on the pathway.
  • S6K1 can also regulate the pathway by catalyzing an inhibitory phosphorylation on insulin receptor substrate proteins (IRS). This prevents IRS from activating PI3K, which indirectly lowers activation of AKT.
  • IRS insulin receptor substrate proteins
  • PI3K, AKT and mTOR In addition to the well described PI3K/AKT/mTOR axis of the PI3K signaling pathway, PI3K, AKT and mTOR also receive and branch differential signaling events that are independent from the axis. For example, mTOR has the crosstalk with and is activated by MAPK pathway through ERK and RSK regulated phosphorylation of TSC2. 17 There are collective data describing the AKT/mTOR-independent PI3K-mediated signaling events.
  • PI3K downstream signaling molecule PDK1 responses to increased levels of PIP3 and activates not only AKT, but also a group of AGC kinases comprising S6K, RSK, SGK and PKC isoforms, which play essential roles in regulating tumor cell growth, proliferation, survival and metabolism.
  • AGC kinases comprising S6K, RSK, SGK and PKC isoforms.
  • many PIK3CA mutant cancer cell lines and human breast tumors exhibit only minimal AKT activation and a diminished reliance on AKT for anchorage-independent growth. Instead, these cells retain robust PDK1 activation and membrane localization and exhibit dependency on the PDK1 substrate SGK3.
  • SGK3 undergoes PI3K- and PDK1 -dependent activation in PIK3CA mutant cancer cells.
  • PI3K may promote cancer through both AKT-dependent and AKT-independent mechanisms.
  • PI3Ks regulate also other cancer related signaling proteins such as PLC, Rac, Rho, ITK and BTK, etc.
  • class I PI3K has four isoforms of the p1 1 0 catalytic subunits, p1 10cc, ⁇ 1 10 ⁇ , ⁇ 1 10 ⁇ and ⁇ 1 10 ⁇ .
  • ⁇ 1 10 ⁇ and ⁇ 1 10 ⁇ are present in all cell types, while ⁇ 1 10 ⁇ and ⁇ 1 10 ⁇ are highly enriched in leukocytes.
  • p1 10 subunits are divided into a class IA group (p1 10a, p1 10 ⁇ and p1 105), which bind the p85 regulatory subunit, and a class IB group ( ⁇ 1 10 ⁇ ), which does not.
  • the p85 regulatory subunits contain Src homology 2 (SH2) domains and bind phosphorylated tyrosine (pTyr), which lead to the activation of the class IA p1 10 catalytic subunits.
  • SH2 Src homology 2
  • pTyr phosphorylated tyrosine
  • p1 1 0 ⁇ is activated directly through G protein coupled receptors (GPCRs). Recent data indicated that ⁇ 1 10 ⁇ was also activated by GPCRs directly through ⁇ protein.
  • each class I PI3Ks The signaling inputs to each class I PI3Ks are diverse and well depicted in genetic analyses.
  • activation of AKT was impaired in p1 10cc-deficient MEFs upon stimulation by classical RTK ligands (EGF, insulin, IGF-1 , and PDGF).
  • RTK ligands EGF, insulin, IGF-1 , and PDGF.
  • MEFs in which ⁇ 1 10 ⁇ is ablated or replaced by a kinase- dead allele of ⁇ 1 10 ⁇ respond normally to growth factor stimulation via RTKs. 22
  • ⁇ 1 10 ⁇ catalytic activity is actually required for AKT activation in response to GPCR ligands (such as LPA).
  • p1 10a appears to carry the majority of the PI3K signal in classic RTK signaling and is responsible for tumor cell growth, proliferation, survival, angiogenesis and metabolism whereas p1 10 ⁇ mediates GPCR signaling from mitogens and chemokines and therefore may regulate tumor cell proliferation, metabolism, inflammation and invasion.
  • PI3K/AKT kinases Activation of PI3K/AKT kinases promotes increased nutrient uptake, converting cells to a glucose-dependent metabolism that redirects lipid precursors and amino acids to anabolic processes that support cell growth and proliferation.
  • These metabolic phenotype with overactivated AKT lead to malignancies that display a metabolic conversion to aerobic glycolysis (the Warburg effect).
  • the PI3K/AKT pathway is discussed to be central for survival despite unfavourable growth conditions such as glucose depletion or hypoxia.
  • a further aspect of the activated PI3K/AKT pathway is to protect cells from programmed cell death ("apoptosis") and is hence considered to transduce a survival signal.
  • apoptosis programmed cell death
  • the PI3K/AKT pathway By acting as a modulator of anti-apoptotic signalling in tumor cells, the PI3K/AKT pathway, particular PI3K itself is a target for cancer therapy.
  • Activated PI3K/AKT phosphorylates and regulates several targets, e.g. BAD, GSK3 or FKHRL1 , that affect different signalling pathways like cell survival, protein synthesis or cell movement.
  • This PI3K/AKT pathway also plays a major part in resistance of tumor cells to conventional anti-cancer therapies.
  • Blocking the PI3K/AKT pathway could therefore simultaneously inhibit the proliferation of tumor cells (e.g. via the inhibition of the metabolic effect) and sensitize towards pro-apoptotic agents.
  • PI3K inhibition selectively sensitized tumor cells to apoptotic stimuli like Trail, Campthothecin and Doxorubicin.
  • PI3K/AKT pathway is linked to resistance to both chemo- and targeted therapeutics.
  • the Inhibition of ⁇ 3 ⁇ might present a promising strategy to overcome the resistance to radiation and DNA targeting therapy.
  • Nuclear PI3Kb can induce nuclear AKT phosphorylated on both T308 and S473 in response to either IR or the DNA-damaging agent doxorubicin.
  • PI3K plays central role downstream of many cancer related signaling pathways that are critical for tumorigenesis, tumor growth / proliferation and survival, tumor cell adhesion, invation and metastasis, as well as tumor angiogenesis.
  • PIK3CA gain-function mutation of PIK3CA is common in several human cancers and the link between tumor suppressor gene PTEN and ⁇ 3 ⁇ has been observed in some tumors such as prostate cancer.
  • An increased expression of the ⁇ 1 10 ⁇ and ⁇ 1 1 0 ⁇ isoforms has been observed in some colon and bladder tumors, and in glioblastoma.
  • nuclear ⁇ 3 ⁇ plays roles in DNA synthesis and repair.
  • ⁇ 1 10 ⁇ controls proliferation in acute myeloid leukemia (AML) and migration of breast cancer cells, 36 whereas ⁇ 1 10 ⁇ plays roles in tumor angiogenesis, drug resistance of CML cells, and pancreatic tumor growth and survival. 37
  • AML acute myeloid leukemia
  • ⁇ 1 10 ⁇ plays roles in tumor angiogenesis, drug resistance of CML cells, and pancreatic tumor growth and survival.
  • inhibitors of PI3K represent valuable compounds that should complement therapeutic options as single agents and also in combination with other drugs, e.g. DNA targeting agent and radiation therapy. It has been surprisingly found, that the compounds of general formula (I) as described herein are effective in the treatment or prophylaxis of cancer, particularly breast cancer, prostate cancer, multiple myeloma, hepatocyte carcinoma, lung cancer, in particular non-small cell lung carcinoma, colorectal cancer, melanoma, pancreatic cancer, particularly where such cancers show metastases.
  • cancer particularly breast cancer, prostate cancer, multiple myeloma, hepatocyte carcinoma, lung cancer, in particular non-small cell lung carcinoma, colorectal cancer, melanoma, pancreatic cancer, particularly where such cancers show metastases.
  • the compounds of general formula (I) are effective in the treatment or prophylaxis of cancer, particularly breast cancer, prostate cancer, multiple myeloma, hepatocyte carcinoma, lung cancer, in particular non- small cell lung carcinoma, colorectal cancer, melanoma, pancreatic cancer with bone metastases.
  • PI3K inhibitor of general formula (I) or a physiologically acceptable salt, solvate, hydrate or stereoisomer as a sole agent showed a statistically significant reduction in whole body tumor burden. Further, a reduction in total tumor-induced osteolytic and osteoblast lesion area in bone was also observed. Moreover, a significant reduction in kidney metastases was observed with a PI3K inhibitor of the present invention as monotherapy.
  • the present invention provides the use of a compound of general formula (I),
  • R 1 represents -(CH 2 )n-(CH R 4 )-(CH2)m-N(R 5 )(R 5 ) ;
  • R 2 represents a heteroaryl of structure :
  • X represents N or C-R 6 .
  • X' represents O, S, NH, N-R 6 , N or C-R 6 ,
  • R 3 is methyl
  • R 4 is hydroxy
  • R 5 and R 5' are the same or different and are, independently of each other, a hydrogen atom, or a Ci-Ce-alkyl, Ca-Ce-cycloalkyl-Ci -Ce-alkyl, or Ci-Ce-alkoxy- Ci-Ce-alkyl,
  • R 5 and R 5' taken together with the nitrogen atom to which they are bound, represent a 3- to 7-membered nitrogen containing heterocyclic ring optionally containing at least one additional heteroatom selected from oxygen, nitrogen or sulfur and which may be optionally substituted with 1 or more R 6' groups ; each occurrence of R 6 may be the same or different and is independently a hydrogen atom, a halogen atom, Ci-Ce-alkyl, C2-C6-alkenyl, C2-C6-alkynyl, C3- Ce-cycloalkyl, Ca-Ce-cycloalkyl-Ci-Ce-alkyl, aryl, aryl-Ci -Ce-alkyl, heteroaryl, heteroaryl-Ci -Ce-alkyl, 3- to 8-membered heterocyclic ring, 3- to 8-membered heterocyclyl-O-Ce-alkyl, -Ci-Ce-alkyl-OR 7 , -
  • * represents the point of attachment with the rest of the structure of general formula (I), as a sole active agent, or a stereoisomer, a tautomer, an N-oxide, a hydrate, a solvate, or a salt thereof, in particular a physiologically acceptable salt, for the preparation of a medicament for the treatment or prophylaxis of cancer, particularly breast cancer, prostate cancer, multiple myeloma, hepatocyte carcinoma, lung cancer, in particular non-small cell lung carcinoma, colorectal cancer, melanoma, pancreatic cancer and/or metastases thereof.
  • cancer particularly breast cancer, prostate cancer, multiple myeloma, hepatocyte carcinoma, lung cancer, in particular non-small cell lung carcinoma, colorectal cancer, melanoma, pancreatic cancer and/or metastases thereof.
  • R 1 represents -(CH2)n-(CHR 4 )-(CH2)m-N(R 5 )(R 5 ) ;
  • R 2 represents a heteroaryl of structure :
  • R 3 is methyl
  • R 4 is hydroxy
  • R 5 and R 5' are the same or different and are, independently of each other, a hydrogen atom, or a Ci-Ce-alkyl, Ca-Ce-cycloalkyl-Ci-Ce-alkyl, or Ci-Ce-alkoxy- Ci-Ce-alkyl,
  • R 5 and R 5' taken together with the nitrogen atom to which they are bound, represent a 3- to 7-membered nitrogen containing heterocyclic ring optionally containing at least one additional heteroatom selected from oxygen, nitrogen or sulfur and which may be optionally substituted with 1 or more R 6' groups ; each occurrence of R 6 may be the same or different and is independently a hydrogen atom, a halogen atom, Ci-Ce-alkyl, C2-C6-alkenyl, C2-C6-alkynyl, C3- Ce-cycloalkyl, Ca-Ce-cycloalkyl-Ci-Ce-alkyl, aryl, aryl-Ci-Ce-alkyl, heteroaryl, heteroaryl-Ci-Ce-alkyl, 3- to 8-membered heterocyclic ring, 3- to 8-membered heterocyclyl-Ci-Ce-alkyl, -Ci-Ce-alkyl-OR 7 , -C
  • * represents the point of attachment with the rest of the structure of general formula (I), or a stereoisomer, a tautomer, an N-oxide, a hydrate, a solvate, or a salt thereof, in particular a physiologically acceptable salt.
  • the compound of general formula (I) is selected from the group consisting of :
  • the compound of general formula (I) is selected from the group consisting of :
  • R 1 represents -(CH2)n-(CHR 4 )-(CH2)m-N(R 5 )(R 5 ) ;
  • R 2 represents a heteroaryl of structure :
  • R 3 is methyl
  • R 4 is hydroxy
  • R 5 and R 5' are the same or different and are, independently of each other, a hydrogen atom, or a Ci-Ce-alkyl, Cs-Ce-cycloalkyl-Ci -Ce-alkyl, or Ci-Ce-alkoxy- Ci-Ce-alkyl,
  • R 5 and R 5' taken together with the nitrogen atom to which they are bound, represent a 3- to 7-membered nitrogen containing heterocyclic ring optionally containing at least one additional heteroatom selected from oxygen, nitrogen or sulfur and which may be optionally substituted with 1 or more R 6' groups ; each occurrence of R 6 may be the same or different and is independently a hydrogen atom, a halogen atom, Ci-Ce-alkyl, C2-C6-alkenyl, C2-C6-alkynyl, C3- Ce-cycloalkyl, Ca-Ce-cycloalkyl-Ci-Ce-alkyl, aryl, aryl-Ci -Ce-alkyl, heteroaryl, heteroaryl-Ci -Ce-alkyl, 3- to 8-membered heterocyclic ring, 3- to 8-membered heterocyclyl-O-Ce-alkyl, -Ci-Ce-alkyl-OR 7 , -
  • the compound of general formula (I) is selected from the group consisting of :
  • the compound of general formula (I) is N-(8- ⁇ [(2R)-2-hydroxy-3-(morpholin-4-yl)propyl]oxy ⁇ -7-methoxy-2,3- dihydroimidazo[1 ,2-c]quinazolin-5-yl)-2-methylpyridine-3-carboxamide, or a stereoisomer, a tautomer, an N-oxide, a hydrate, a solvate, or a salt thereof, in particular a physiologically acceptable salt.
  • the invention encompasses the use of a compound of general formula (I), as described supra, for the preparation of a medicament for the treatment or prophylaxis of cancer.
  • the invention encompasses the use of a compound of general formula (I), as described supra, for the preparation of a medicament for the treatment or prophylaxis of breast cancer or prostate cancer and/or metastases thereof.
  • the metastases are bone metastases.
  • the compound of general formula (I) is selected from the group of PI3K inhibitors generically or specifically disclosed in WO2012062748 A1 , which are incorporated by reference herein.
  • the present invention covers a combination of : a) a compound of general formula (I) as described supra, or a stereoisomer, a tautomer, an N-oxide, a hydrate, a solvate, or a salt thereof, in particular a physiologically acceptable salt; or a pharmaceutical composition containing such a compound or a stereoisomer, a tautomer, an N-oxide, a hydrate, a solvate, or a salt thereof, in particular a physiologically acceptable salt,
  • anti-angiogenesis anti-hyper-proliferative, antiinflammatory, analgesic, immunoregulatory, diuretic, antiarrhytmic, anti-hypercholsterolemia, anti- dyslipidemia, anti-diabetic or antiviral agents, and/or admixtures or combinations thereof.
  • the present invention comprises a pharmaceutical composition which comprises a combination of :
  • one or more further active agents selected from the group consisting of : anti-angiogenesis, anti-hyper-proliferative, antiinflammatory, analgesic, immunoregulatory, diuretic, antiarrhytmic, anti-hypercholsterolemia, anti- dyslipidemia, anti-diabetic or antiviral agents, and/or admixtures or combinations thereof.
  • the present invention relates to the use of a combination of :
  • anti-angiogenesis anti-hyper-proliferative, antiinflammatory, analgesic, immunoregulatory, diuretic, antiarrhytmic, anti-hypercholsterolemia, anti- dyslipidemia, anti-diabetic or antiviral agents, and/or admixtures or combinations thereof,
  • a cancer particularly breast cancer, prostate cancer, multiple myeloma, hepatocyte carcinoma, lung cancer, in particular non-small cell lung carcinoma, colorectal cancer, melanoma, pancreatic cancer and/or metastases thereof.
  • the use of the combination as described supra is for the preparation of a medicament for the treatment or prophylaxis of breast cancer or prostate cancer and/or metastases thereof.
  • the metastases are bone metastases.
  • the present invention relates to a method of treatment or prophylaxis of a cancer, particularly multiple myeloma, hepatocyte carcinoma, lung cancer, in particular non-small cell lung carcinoma, colorectal cancer, melanoma, pancreatic cancer, prostate cancer, breast cancer and/or metastases thereof, in a subject, comprising administering to said subject a therapeutically effective amount of a compound of general formula (I) as described herein.
  • the method is for the treatment or prophylaxis of breast cancer or prostate cancer and/or metastases thereof.
  • the metastases are bone metastases.
  • the present invention relates to :
  • a kit comprising a combination of :
  • anti-angiogenesis anti-hyper-proliferative, antiinflammatory, analgesic, immunoregulatory, diuretic, antiarrhytmic, anti-hypercholsterolemia, anti- dyslipidemia, anti-diabetic or antiviral agents, and/or admixtures or combinations thereof, in which optionally both or either of said compounds of general formula (I) and further active agents are in the form of a pharmaceutical formulation which is ready for use to be administered simultaneously, concurrently, separately or sequentially.
  • halogen atom or halo is to be understood as meaning a fluorine, chlorine, bromine or iodine atom.
  • Ci -Ce-alkyl is to be understood as preferably meaning a linear or branched, saturated, monovalent hydrocarbon group having 1 , 2, 3, 4, 5 or 6 carbon atoms, e.g. a methyl, ethyl, propyl, butyl, pentyl, hexyl, iso-propyl, iso- butyl, sec-butyl, tert-butyl, iso-pentyl, 2-methylbutyl, 1 -methylbutyl, 1 -ethylpropyl, 1 ,2-dimethylpropyl, neo-pentyl, 1 ,1 -dimethylpropyl, 4-methylpentyl, 3- methylpentyl, 2-methylpentyl, 1 -methylpentyl, 2-ethylbutyl, 1 -ethylbutyl, 3,3- dimethylbutyl, 2,2-dimethylbutyl, 1 ,1
  • Ci -Ce-alkoxy is to be understood as preferably meaning a linear or branched, saturated, monovalent, hydrocarbon group of formula -O-alkyl, in which the term “alkyl” is defined supra, e.g. a methoxy, ethoxy, n-propoxy, iso- propoxy, n-butoxy, iso-butoxy, tert-butoxy, sec-butoxy, pentoxy, iso-pentoxy, or n-hexoxy group, or an isomer thereof.
  • Ci-Ce-alkoxy-Ci-Ce-alkyI is to be understood as preferably meaning a linear or branched, saturated, monovalent alkyl group, as defined supra, in which one or more of the hydrogen atoms is replaced, in identically or differently, by a Ci -Ce-alkoxy group, as defined supra, e.g.
  • C2-Ce-alkenyl is to be understood as preferably meaning a linear or branched, monovalent hydrocarbon group, which contains one or more double bonds, and which has 2, 3, 4, 5, or 6 carbon atoms, particularly 2 or 3 carbon atoms (“C2-C3-alkenyl”), it being understood that in the case in which said alkenyl group contains more than one double bond, then said double bonds may be isolated from, or conjugated with, each other.
  • Said alkenyl group is, for example, a vinyl, allyl, (E)-2-methylvinyl, (Z)-2-methylvinyl, homoallyl, (E)-but-2- enyl, (Z)-but-2-enyl, (E)-buM -enyl, (Z)-buM -enyl, pent-4-enyl, (E)-pent-3-enyl, (Z)-pent-3-enyl, (E)-pent-2-enyl, (Z)-pent-2-enyl, (E)-penM -enyl, (Z)-penM - enyl, hex-5-enyl, (E)-hex-4-enyl, (Z)-hex-4-enyl, (E)-hex-3-enyl, (Z)-hex-3-enyl, (E)-hex-2-enyl, (Z)-hex-2-enyl, (
  • C2-C6-alkynyl is to be understood as preferably meaning a linear or branched, monovalent hydrocarbon group which contains one or more triple bonds, and which contains 2, 3, 4, 5, or 6 carbon atoms, particularly 2 or 3 carbon atoms ("C2-C3-alkynyl").
  • Said C2-Ce-alkynyl group is, for example, ethynyl, prop-1 -ynyl, prop-2-ynyl, but-1 -ynyl, but-2-ynyl, but-3-ynyl, pent-1 -ynyl, pent-2-ynyl, pent-3-ynyl, pent-4-ynyl, hex-1 -ynyl, hex-2-inyl, hex-3-inyl, hex-4- ynyl, hex-5-ynyl, 1 -methylprop-2-ynyl, 2-methylbut-3-ynyl, 1 -methylbut-3-ynyl, 1 - methylbut-2-ynyl, 3-methylbut-1 -ynyl, 1 -ethylprop-2-ynyl, 3-methylpent-4-ynyl, 2- methylpent-4-ynyl, 1 -
  • said alkynyl group is ethynyl, prop-1 -ynyl, or prop-2-inyl.
  • C3-C6-cycloalkyl is to be understood as preferably meaning a saturated, monovalent, mono-, or bicyclic hydrocarbon ring which contains 3, 4, 5, or 6 carbon atoms.
  • Said C3-Ce-cycloalkyl group is for example, a monocyclic hydrocarbon ring, e.g. a cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl group, or a bicyclic hydrocarbon ring, e.g. a perhydropentalenylene or decalin ring.
  • Said cycloalkyl ring can optionally contain one or more double bonds e.g. cycloalkenyl, such as a cyclopropenyl, cyclobutenyl, cyclopentenyl or cyclohexenyl group, wherein the bond between said ring with the rest of the molecule may be to any carbon atom of said ring, be it saturated or unsaturated.
  • alkylene is understood as preferably meaning an optionally substituted hydrocarbon chain (or "tether”) having 1 , 2, 3, 4, 5, or 6 carbon atoms, i.e.
  • -CH2- an optionally substituted -CH2- ("methylene” or “single membered tether” or, for example -C(Me)2-), -CH2-CH2- ("ethylene”, “dimethylene”, or “two- membered tether"), -CH2-CH2-CH2- ("propylene”, “trimethylene”, or “three- membered tether"), -CH2-CH2-CH2- ("butylene”, “tetramethylene”, or “four- membered tether"), -CH2-CH2-CH2-CH2- (“pentylene”, “pentamethylene” or “five-membered ether"), or -CH2-CH2-CH2-CH2-CH2- ("hexylene”, “hexamethylene”, or six-membered tether”) group.
  • said alkylene tether has 1 , 2, 3, 4, or 5 carbon atoms, more particularly 1 or 2 carbon atoms.
  • said 3- to 8-membered heterocycloalkyi can contain 2, 3, 4, 5, 6 or 7 carbon atoms, and one or more of the above-mentioned heteroatom-containing groups (a "3- to 8-membered heterocycloalkyi"), more particularly said heterocycloalkyi can contain 4 or 5 carbon atoms, and one or more of the above-mentioned heteroatom-containing groups (a "5- to 7-membered heterocycloalkyi").
  • said heterocycloalkyi can be a 4- membered ring, such as an azetidinyl, oxetanyl, or a 5-membered ring, such as tetrahydrofuranyl, dioxolinyl, pyrrolidinyl, imidazolidinyl, pyrazolidinyl, pyrrolinyl, or a 6-membered ring, such as tetrahydropyranyl, piperidinyl, morpholinyl, dithianyl, thiomorpholinyl, piperazinyl, or trithianyl, or a 7-membered ring, such as a diazepanyl ring, for example.
  • said heterocycloalkyi can be benzo fused.
  • Said heterocyclyl can be bicyclic, such as, without being limited thereto, a 5,5- membered ring, e.g. a hexahydrocyclopenta[c]pyrrol-2(1 H)-yl) ring, or a 5,6- membered bicyclic ring, e.g. a hexahydropyrrolo[1 ,2-a]pyrazin-2(1 H)-yl ring, or 8-oxa-3-azabicyclo[3.2.1 ]oct-3-yl ring, for example.
  • a 5,5- membered ring e.g. a hexahydrocyclopenta[c]pyrrol-2(1 H)-yl) ring
  • a 5,6- membered bicyclic ring e.g. a hexahydropyrrolo[1 ,2-a]pyrazin-2(1 H)-yl ring
  • said nitrogen atom-containing ring can be partially unsaturated, i.e. it can contain one or more double bonds, such as, without being limited thereto, a 2,5-dihydro-1 H-pyrrolyl, 4H-[1 ,3,4]thiadiazinyl, 4,5- dihydrooxazolyl, or 4H-[1 ,4]thiazinyl ring, for example, or, it may be benzo-fused, such as, without being limited thereto, a dihydroisoquinolinyl ring, for example.
  • aryl is to be understood as preferably meaning a monovalent, aromatic or partially aromatic, mono-, or bi- or tricyclic hydrocarbon ring having 6, 7, 8, 9, 10, 1 1 , 12, 13 or 14 carbon atoms (a "Ce-Cn-aryl” group), particularly a ring having 6 carbon atoms (a "Ce-aryl” group), e.g. a phenyl group; or a biphenyl group, or a ring having 9 carbon atoms (a "Cg-aryl” group), e.g. an indanyl or indenyl group, or a ring having 1 0 carbon atoms (a "Cio-aryl” group), e.g.
  • a particular example of an aryl group is one of the following possible structures : in which z represents O, S, NH or N(Ci-C6-alkyl), and * indicates the point of attachment of said aryl group with the rest of the molecule.
  • heteroaryl is understood as preferably meaning a monovalent, monocyclic- , bicyclic- or tricyclic aromatic ring system having 5, 6, 7, 8, 9, 10, 1 1 , 12, 13 or 14 ring atoms (a "5- to 14-membered heteroaryl” group), particularly 5 or 6 or 9 or 10 atoms, and which contains at least one heteroatom which may be identical or different, said heteroatom being such as oxygen, nitrogen or sulfur, and in addition in each case can be benzocondensed.
  • heteroaryl is of structure :
  • X represents N or C-R 6 .
  • X' represents O, S, NH, N-R 6 , N or C-R 6 ,
  • R 6 may be the same or different and is independently a hydrogen atom, a halogen atom, Ci-Ce-alkyl, C2-C6-alkenyl, C2-C6-alkynyl, C3- Ce-cycloalkyl, Ca-Ce-cycloalkyl-Ci-Ce-alkyl, aryl, aryl-Ci -Ce-alkyl, heteroaryl, heteroaryl-Ci -Ce-alkyl, 3- to 8-membered heterocyclic ring, 3- to 8-membered heterocyclyl-O-Ce-alkyl, -Ci-Ce-alkyl-OR 7 , -Ci-Ce-alkyl-SR 7 , -Ci -Ce-alkyl- N(R )(R 7 ), ), -OR 7 , -SR 7 , -N(R 7 )(R 7' ), or -N R 7 C
  • R 7 and R 7' may be the same or different and is independently a hydrogen atom, or a Ci -Ce-alkyl, C2-C6-alkenyl, C2-C6-alkynyl, C3-C6-cycloalkyl, C3-Ce-cycloalkyl-Ci-Ce-alklyl, C3-C6-cycloalkenyl, aryl, aryl-Ci- Ce-alkyl, heteroaryl, 3- to 8-membered heterocyclic ring, 3- to 8-membered heterocyclyl-Ci-Ce-alkyl, or heteroaryl-Ci-Ce-alkyl ;
  • R 8 is independently a halogen atom, or nitro, hydroxy, cyano, formyl, acetyl, amino, Ci-Ce-alkyl, Ci-Ce-alkoxy, C2-C6-alkenyl, C2-C6- alkynyl, C3-C6-cycloalkyl, Cs-Ce-cycloalkyl-Ci-Ce-alkyl, Ci-Ce-cycloalkenyl, aryl, aryl-Ci-Ce-alkyl, heteroaryl, 3- to 8-membered heterocyclic ring, heterocyclyl-Ci- Ce-alkyl, or heteroaryl-Ci-Ce-alkyl.
  • said heteroaryl is selected from thienyl, furanyl, pyrrolyl, oxazolyl, thiazolyl, imidazolyl, pyrazolyl, isoxazolyl, isothiazolyl, oxadiazolyl, triazolyl, thiadiazolyl, thia-4H-pyrazolyl etc., and benzo derivatives thereof, such as, for example, benzofuranyl, benzothienyl, benzoxazolyl, benzisoxazolyl, benzimidazolyl, benzotriazolyl, indazolyl, indolyl, isoindolyl, etc.; or pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl, etc., and benzo derivatives thereof, such as, for example, quinolinyl, quinazolinyl, isoquinolinyl, etc.
  • the heteroarylic or heteroarylenic radicals include all the possible isomeric forms thereof, e.g. the positional isomers thereof.
  • the term pyridinyl or pyridinylene includes pyridin-2-yl, pyridin-2-ylene, pyridin-3-yl, pyridin-3-ylene, pyridin-4-yl and pyridin-4-ylene; or the term thienyl or thienylene includes thien-2-yl, thien-2-ylene, thien-3-yl and thien-3-ylene.
  • Ci-Ce as used throughout this text, e.g. in the context of the definition of "Ci-Ce-alkyl” or “Ci-Ce-alkoxy” is to be understood as meaning an alkyl group having a finite number of carbon atoms of 1 to 6, i.e. 1 , 2, 3, 4, 5, or 6 carbon atoms. It is to be understood further that said term “Ci-Ce” is to be interpreted as any sub-range comprised therein, e.g.
  • C2-C6 as used throughout this text, e.g. in the context of the definitions of "C2-C6-alkenyl” and “C2-C6-alkynyl”, is to be understood as meaning an alkenyl group or an alkynyl group having a finite number of carbon atoms of 2 to 6, i.e. 2, 3, 4, 5, or 6 carbon atoms. It is to be understood further that said term “C2-C6” is to be interpreted as any sub-range comprised therein, e.g. C2-C6 , C3-C5 , C3-C , C2-C3 , C2-C , C2-C5 ; particularly
  • C3-C6 as used throughout this text, e.g. in the context of the definition of "C3-C6-cycloalkyl”, is to be understood as meaning a cycloalkyi group having a finite number of carbon atoms of 3 to 6, i.e. 3, 4, 5 or 6 carbon atoms. It is to be understood further that said term “C3-C6” is to be interpreted as any sub-range comprised therein, e.g. C3-C6 , C -Cs , C3-C5 , C3-C , C -Ce, C5-C6 ; particularly C3-C6.
  • substituted means that one or more hydrogens on the designated atom is replaced with a selection from the indicated group, provided that the designated atom's normal valency under the existing circumstances is not exceeded, and that the substitution results in a stable compound. Combinations of substituents and/or variables are permissible only if such combinations result in stable compounds.
  • Ring system substituent means a substituent attached to an aromatic or nonaromatic ring system which, for example, replaces an available hydrogen on the ring system.
  • the term "one or more times”, e.g. in the definition of the substituents of the compounds of the present invention, is understood as meaning “one, two, three, four or five times, particularly one, two, three or four times, more particularly one, two or three times, even more particularly one or two times”.
  • stable compound' or “stable structure” is meant a compound that is sufficiently robust to survive isolation to a useful degree of purity from a reaction mixture, and formulation into an efficacious therapeutic agent.
  • carbonyl refers to an oxygen atom bound to a carbon atom of the molecule by a double bond.
  • the compounds of this invention may contain one or more asymmetric centers, depending upon the location and nature of the various substituents desired.
  • Asymmetric carbon atoms may be present in the (f?)- and/or (SJ-configuration, resulting in racemic mixtures in the case of a single asymmetric center, and diastereomeric mixtures in the case of multiple asymmetric centers.
  • asymmetry may also be present due to restricted rotation about a given bond, for example, the central bond adjoining two substituted aromatic rings of the specified compounds.
  • Substituents on a ring may also be present in either cis or trans form. It is intended that all such configurations (including enantiomers and diastereomers), are included within the scope of the present invention.
  • Preferred compounds are those, which produce the more desirable biological activity.
  • Separated, pure or partially purified isomers and stereoisomers or racemic or diastereomeric mixtures of the compounds of this invention are also included within the scope of the present invention.
  • the purification and the separation of such materials can be accomplished by standard techniques known in the art.
  • Tautomers are two or more compounds that are related by the migration of a hydrogen atom accompanied by the switch of one or more single bonds and one or more adjacent double bonds.
  • the compounds of this invention may exist in one or more tautomeric forms.
  • a compound of Formula I may exist in tautomeric form la, tautomeric form lb, or tautomeric form Ic, or may exist as a mixture of any of these forms. It is intended that all such tautomeric forms are included within the scope of the present invention.
  • the present invention also relates to useful forms of the compounds as disclosed herein, such as pharmaceutically acceptable salts, co-precipitates, metabolites, hydrates, solvates and prodrugs of all the compounds of examples.
  • pharmaceutically acceptable salt refers to a relatively non-toxic, inorganic or organic acid addition salt of a compound of the present invention. For example, see S. M. Berge, et al. "Pharmaceutical Salts," J. Pharm. Sci. 1977, 66, 1 -19.
  • Pharmaceutically acceptable salts include those obtained by reacting the main compound, functioning as a base, with an inorganic or organic acid to form a salt, for example, salts of hydrochloric acid, sulfuric acid, phosphoric acid, methane sulfonic acid, camphor sulfonic acid, oxalic acid, maleic acid, succinic acid and citric acid.
  • Pharmaceutically acceptable salts also include those in which the main compound functions as an acid and is reacted with an appropriate base to form, e.g., sodium, potassium, calcium, magnesium, ammonium, and chorine salts.
  • acid addition salts of the claimed compounds may be prepared by reaction of the compounds with the appropriate inorganic or organic acid via any of a number of known methods.
  • alkali and alkaline earth metal salts of acidic compounds of the invention are prepared by reacting the compounds of the invention with the appropriate base via a variety of known methods.
  • Representative salts of the compounds of this invention include the conventional non-toxic salts and the quaternary ammonium salts which are formed, for example, from inorganic or organic acids or bases by means well known in the art.
  • such acid addition salts include acetate, adipate, alginate, ascorbate, aspartate, benzoate, benzenesulfonate, bisulfate, butyrate, citrate, camphorate, camphorsulfonate, cinnamate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, fumarate, glucoheptanoate, glycerophosphate, hemisulfate, heptanoate, hexanoate, chloride, bromide, iodide, 2-hydroxyethanesulfonate, itaconate, lactate, maleate, mandelate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, oxalate, pamoate, pectinate, persulfate, 3-phenylpropionate, picrate
  • Base salts include alkali metal salts such as potassium and sodium salts, alkaline earth metal salts such as calcium and magnesium salts, and ammonium salts with organic bases such as dicyclohexylamine and N-methyl-D-glucamine. Additionally, basic nitrogen containing groups may be quaternized with such agents as lower alkyl halides such as methyl, ethyl, propyl, or butyl chlorides, bromides and iodides; dialkyi sulfates like dimethyl, diethyl, dibutyl sulfate, or diamyl sulfates, long chain halides such as decyl, lauryl, myristyl and strearyl chlorides, bromides and iodides, aralkyl halides like benzyl and phenethyl bromides and others.
  • lower alkyl halides such as methyl, ethyl, propyl, or butyl chlorides,
  • a solvate for the purpose of this invention is a complex of a solvent and a compound of the invention in the solid state.
  • Exemplary solvates would include, but are not limited to, complexes of a compound of the invention with ethanol or methanol. Hydrates are a specific form of solvate wherein the solvent is water. Constituents which are optionally substituted as stated herein, may be substituted, unless otherwise noted, one or more times, independently from one another at any possible position. When any variable occurs more than one time in any constituent, each definition is independent.
  • heteroarylic, or heterocyclic groups mentioned herein can be substituted by their given substituents or parent molecular groups, unless otherwise noted, at any possible position, such as e.g. at any substitutable ring carbon or ring nitrogen atom. Analogously it is being understood that it is possible for any heteroaryl or heterocyclyl group to be attached to the rest of the molecule via any suitable atom if chemically suitable. Unless otherwise noted, any heteroatom of a heteroarylic ring with unsatisfied valences mentioned herein is assumed to have the hydrogen atom(s) to satisfy the valences.
  • rings containing quaternizable amino- or imino-type ring nitrogen atoms may be preferably not quaternized on these amino- or imino-type ring nitrogen atoms by the mentioned substituents or parent molecular groups.
  • Preferred compounds are those which produce the more desirable biological activity.
  • Separated, pure or partially purified isomers and stereoisomers or racemic or diastereomeric mixtures of the compounds of this invention are also included within the scope of the present invention.
  • the purification and the separation of such materials can be accomplished by standard techniques already known in the art.
  • the optical isomers can be obtained by resolution of the racemic mixtures according to conventional processes, for example, by the formation of diastereoisomeric salts using an optically active acid or base or formation of covalent diastereomers.
  • Examples of appropriate acids are tartaric, diacetyltartaric, ditoluoyltartaric and camphorsulfonic acid.
  • optically active bases or acids are then liberated from the separated diastereomeric salts.
  • a different process for separation of optical isomers involves the use of chiral chromatography (e.g., chiral HPLC columns), with or without conventional derivatisation, optimally chosen to maximise the separation of the enantiomers. Suitable chiral HPLC columns are manufactured by Diacel, e.g., Chiracel OD and Chiracel OJ among many others, all routinely selectable. Enzymatic separations, with or without derivatisation, are also useful.
  • the optically active compounds of this invention can likewise be obtained by chiral syntheses utilizing optically active starting materials. If in the context of the invention "embodiment" is mentioned it should be understood to include a plurality of possible combinations.
  • the invention also includes all suitable isotopic variations of a compound of the invention.
  • An isotopic variation of a compound of the invention is defined as one in which at least one atom is replaced by an atom having the same atomic number but an atomic mass different from the atomic mass usually or predominantly found in nature.
  • isotopes that can be incorporated into a compound of the invention include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, sulphur, fluorine, chlorine, bromine and iodine, such as 2 H (deuterium), 3 H (tritium), C, 13 C, 14 C, 15 N, 7 0, 18 0, 32 P, 33 P, 33 S, 34 S, 35 S, 36 S, 18 F, 36 CI, 82 Br, 123 l, 124 l, 129 l and 131 1, respectively.
  • Certain isotopic variations of a compound of the invention for example, those in which one or more radioactive isotopes such as 3 H or 14 C are incorporated, are useful in drug and/or substrate tissue distribution studies.
  • Tritiated and carbon-14, i.e., 1 C, isotopes are particularly preferred for their ease of preparation and detectability. Further, substitution with isotopes such as deuterium may afford certain therapeutic advantages resulting from greater metabolic stability, for example, increased in vivo half-life or reduced dosage requirements and hence may be preferred in some circumstances.
  • Isotopic variations of a compound of the invention can generally be prepared by conventional procedures known by a person skilled in the art such as by the illustrative methods or by the preparations described in the examples hereafter using appropriate isotopic variations of suitable reagents.
  • the present invention includes all possible stereoisomers of the compounds of the present invention as single stereoisomers, or as any mixture of said stereoisomers, in any ratio.
  • Isolation of a single stereoisomer, e.g. a single enantiomer or a single diastereomer, of a compound of the present invention may be achieved by any suitable state of the art method, such as chromatography, especially chiral chromatography, for example.
  • the present invention includes all possible tautomers of the compounds of the present invention as single tautomers, or as any mixture of said tautomers, in any ratio.
  • the present invention includes all possible crystalline forms, or polymorphs, of the compounds of the present invention, either as single polymorphs, or as a mixture of more than one polymorphs, in any ratio.
  • the asymmetric carbon to which R 4 is bonded has the (/ ⁇ -configuration in the compound of formula (I), as described herein.
  • the asymmetric carbon to which R 4 is bonded has the (SJ-configuration in the compound of formula (I), as described herein.
  • the PI3K inhibitor is selected from the group of PI3K inhibitors consisting of buparlisib, idelalisib, BYL-719, dactolisib, PF-05212384, pictilisib, copanlisib, copanlisib dihydrochloride, ZSTK-474, GSK-2636771 , duvelisib, GS-9820, PF-04691502, SAR-245408, SAR-245409, sonolisib, Archexin, GDC-0032, GDC-0980, apitolisib, pilaralisib, DLBS 1425, PX-866, voxtalisib, AZD-8186, BGT-226, DS-7423, GDC-0084, GSK-21 26458, INK-1 1 17, SAR-260301 , SF-1 1 26, AMG-319, BAY-1082439, CH-51 32799, GSK-2
  • the benefitial effect of the present invention is demonstrated herein with one of the PI3K inhibitors specifically disclosed in the Examples section, as example 14, of WO 2012/062748, referrred to as Compound A1 (or as Compd A1 ) below.
  • the compounds of the present invention may be administered, independently of one another when in combination, by the oral, intravenous, topical, local installations, intraperitoneal or nasal route.
  • Compounds of general formula (I) are administered intravenously, intraperitoneal ⁇ , preferably they are administered orally.
  • pharmaceutically or physiologically acceptable salt of a compound refers to a relatively non-toxic, inorganic or organic acid addition salt of a compound of the present invention.
  • Pharmaceutically acceptable salts include those obtained by reacting the main compound, functioning as a base, with an inorganic or organic acid to form a salt, for example, salts of hydrochloric acid, sulfuric acid, phosphoric acid, methane sulfonic acid, camphor sulfonic acid, oxalic acid, maleic acid, succinic acid and citric acid.
  • Pharmaceutically acceptable salts also include those in which the main compound functions as an acid and is reacted with an appropriate base to form, e.g., sodium, potassium, calcium, magnesium, ammonium, and chorine salts.
  • an appropriate base e.g., sodium, potassium, calcium, magnesium, ammonium, and chorine salts.
  • acid addition salts of the claimed compounds may be prepared by reaction of the compounds with the appropriate inorganic or organic acid via any of a number of known methods.
  • alkali and alkaline earth metal salts of acidic compounds of the invention are prepared by reacting the compounds of the invention with the appropriate base via a variety of known methods.
  • Representative salts of a compound of this invention include the conventional non-toxic salts and the quaternary ammonium salts which are formed, for example, from inorganic or organic acids or bases by means well known in the art.
  • acid addition salts include acetate, adipate, alginate, ascorbate, aspartate, benzoate, benzenesulfonate, bisulfate, butyrate, citrate, camphorate, camphorsulfonate, cinnamate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, fumarate, glucoheptanoate, glycerophosphate, hemisulfate, heptanoate, hexanoate, chloride, bromide, iodide, 2-hydroxyethanesulfonate, itaconate, lactate, maleate, mandelate, methanesulfonate, 2-n
  • Base salts include alkali metal salts such as potassium and sodium salts, alkaline earth metal salts such as calcium and magnesium salts, and ammonium salts with organic bases such as dicyclohexylamine and N-methyl-D-glucamine. Additionally, basic nitrogen containing groups may be quaternized with such agents as lower alkyl halides such as methyl, ethyl, propyl, or butyl chlorides, bromides and iodides; dialkyi sulfates like dimethyl, diethyl, dibutyl sulfate, or diamyl sulfates, long chain halides such as decyl, lauryl, myristyl and strearyl chlorides, bromides and iodides, aralkyl halides like benzyl and phenethyl bromides and others.
  • lower alkyl halides such as methyl, ethyl, propyl, or butyl chlorides,
  • a solvate for the purpose of this invention is a complex of a solvent and a compound of the invention in the solid state.
  • Exemplary solvates would include, but are not limited to, complexes of a compound of the invention with ethanol or methanol. Hydrates are a specific form of solvate wherein the solvent is water.
  • Compounds of this invention can be tableted with conventional tablet bases such as lactose, sucrose and cornstarch in combination with binders such as acacia, corn starch or gelatin, disintegrating agents intended to assist the breakup and dissolution of the tablet following administration such as potato starch, alginic acid, corn starch, and guar gum, gum tragacanth, acacia, lubricants intended to improve the flow of tablet granulation and to prevent the adhesion of tablet material to the surfaces of the tablet dies and punches, for example talc, stearic acid, or magnesium, calcium or zinc stearate, dyes, coloring agents, and flavoring agents such as peppermint, oil of wintergreen, or cherry flavoring, intended to enhance the aesthetic qualities of the tablets and make them more acceptable to the patient.
  • binders such as acacia, corn starch or gelatin
  • disintegrating agents intended to assist the breakup and dissolution of the tablet following administration such as potato starch, alginic acid, corn starch
  • Suitable excipients for use in oral liquid dosage forms include dicalcium phosphate and diluents such as water and alcohols, for example, ethanol, benzyl alcohol, and polyethylene alcohols, either with or without the addition of a pharmaceutically acceptable surfactant, suspending agent or emulsifying agent.
  • Various other materials may be present as coatings or to otherwise modify the physical form of the dosage unit. For instance tablets, pills or capsules may be coated with shellac, sugar or both.
  • Dispersible powders and granules are suitable for the preparation of an aqueous suspension. They provide the active ingredient in admixture with a dispersing or wetting agent, a suspending agent and one or more preservatives. Suitable dispersing or wetting agents and suspending agents are exemplified by those already mentioned above. Additional excipients, for example those sweetening, flavoring and coloring agents described above, may also be present.
  • Compounds of this invention can also be in the form of oil-in-water emulsions.
  • the oily phase may be a vegetable oil such as liquid paraffin or a mixture of vegetable oils.
  • Suitable emulsifying agents may be (1 ) naturally occurring gums such as gum acacia and gum tragacanth, (2) naturally occurring phosphatides such as soy bean and lecithin, (3) esters or partial esters derived form fatty acids and hexitol anhydrides, for example, sorbitan monooleate, (4) condensation products of said partial esters with ethylene oxide, for example, polyoxyethylene sorbitan monooleate.
  • the emulsions may also contain sweetening and flavoring agents.
  • Oily suspensions can be formulated by suspending the active ingredient in a vegetable oil such as, for example, arachis oil, olive oil, sesame oil or coconut oil, or in a mineral oil such as liquid paraffin.
  • the oily suspensions may contain a thickening agent such as, for example, beeswax, hard paraffin, or cetyl alcohol.
  • the suspensions may also contain one or more preservatives, for example, ethyl or n-propyl p-hydroxybenzoate; one or more coloring agents; one or more flavoring agents; and one or more sweetening agents such as sucrose or saccharin.
  • Syrups and elixirs can be formulated with sweetening agents such as, for example, glycerol, propylene glycol, sorbitol or sucrose. Such formulations may also contain a demulcent, and preservative, such as methyl and propyl parabens and flavoring and coloring agents.
  • sweetening agents such as, for example, glycerol, propylene glycol, sorbitol or sucrose.
  • Such formulations may also contain a demulcent, and preservative, such as methyl and propyl parabens and flavoring and coloring agents.
  • Compounds of this invention can also be administered parenterally, that is, subcutaneously, intravenously, intraocularly, intrasynovially, intramuscularly, or interperitoneally, as injectable dosages of the compound in preferably a physiologically acceptable diluent with a pharmaceutical carrier which can be a sterile liquid or mixture of liquids such as water, saline, aqueous dextrose and related sugar solutions, an alcohol such as ethanol, isopropanol, or hexadecyl alcohol, glycols such as propylene glycol or polyethylene glycol, glycerol ketals such as 2,2-dimethyl-1 ,1 -dioxolane-4-methanol, ethers such as poly(ethylene glycol) 400, an oil, a fatty acid, a fatty acid ester or, a fatty acid glyceride, or an acetylated fatty acid glyceride, with or without the addition of a pharmaceutically acceptable sur
  • Suitable fatty acids include oleic acid, stearic acid, isostearic acid and myristic acid.
  • Suitable fatty acid esters are, for example, ethyl oleate and isopropyl myristate.
  • Suitable soaps include fatty acid alkali metal, ammonium, and triethanolamine salts and suitable detergents include cationic detergents, for example dimethyl dialkyl ammonium halides, alkyl pyridinium halides, and alkylamine acetates; anionic detergents, for example, alkyl, aryl, and olefin sulfonates, alkyl, olefin, ether, and monoglyceride sulfates, and sulfosuccinates; non-ionic detergents, for example, fatty amine oxides, fatty acid alkanolamides, and poly(oxyethylene-oxypropylene)s or ethylene oxide or propylene oxide copolymers; and amphoteric detergents, for example, alkyl- beta-aminopropionates, and 2-alkylimidazoline quarternary ammonium salts, as well as mixtures.
  • suitable detergents include cationic detergents, for example dimethyl dial
  • compositions of this invention will typically contain from about 0.5% to about 25% by weight of the active ingredient in solution. Preservatives and buffers may also be used advantageously. In order to minimize or eliminate irritation at the site of injection, such compositions may contain a non-ionic surfactant having a hydrophile-lipophile balance (HLB) preferably of from about 12 to about 17. The quantity of surfactant in such formulation preferably ranges from about 5% to about 1 5% by weight.
  • the surfactant can be a single component having the above HLB or can be a mixture of two or more components having the desired HLB.
  • surfactants used in parenteral formulations are the class of polyethylene sorbitan fatty acid esters, for example, sorbitan monooleate and the high molecular weight adducts of ethylene oxide with a hydrophobic base, formed by the condensation of propylene oxide with propylene glycol.
  • compositions can be in the form of sterile injectable aqueous suspensions.
  • suspensions may be formulated according to known methods using suitable dispersing or wetting agents and suspending agents such as, for example, sodium carboxymethylcellulose, methylcellulose, hydroxypropylmethyl-cellulose, sodium alginate, polyvinylpyrrolidone, gum tragacanth and gum acacia; dispersing or wetting agents which may be a naturally occurring phosphatide such as lecithin, a condensation product of an alkylene oxide with a fatty acid, for example, polyoxyethylene stearate, a condensation product of ethylene oxide with a long chain aliphatic alcohol, for example, heptadeca-ethyleneoxycetanol, a condensation product of ethylene oxide with a partial ester derived form a fatty acid and a hexitol such as polyoxyethylene sorbitol monooleate, or a condensation product of an ethylene oxide with a partial ester derived from a
  • the sterile injectable preparation can also be a sterile injectable solution or suspension in a non-toxic parenterally acceptable diluent or solvent.
  • Diluents and solvents that may be employed are, for example, water, Ringer's solution, isotonic sodium chloride solutions and isotonic glucose solutions.
  • sterile fixed oils are conventionally employed as solvents or suspending media.
  • any bland, fixed oil may be employed including synthetic mono- or diglycerides.
  • fatty acids such as oleic acid can be used in the preparation of injectables.
  • Compounds of the invention can also be administered in the form of suppositories for rectal administration of the drug.
  • These components can be prepared by mixing the drug with a suitable non-irritation excipient which is solid at ordinary temperatures but liquid at the rectal temperature and will therefore melt in the rectum to release the drug.
  • a suitable non-irritation excipient which is solid at ordinary temperatures but liquid at the rectal temperature and will therefore melt in the rectum to release the drug.
  • Such materials are, for example, cocoa butter and polyethylene glycol.
  • Another formulation employed in the methods of the present invention employs transdermal delivery devices ("patches"). Such transdermal patches may be used to provide continuous or discontinuous infusion of the compounds of the present invention in controlled amounts.
  • the construction and use of transdermal patches for the delivery of pharmaceutical agents is well known in the art (see, e.g., US Patent No. 5,023,252, issued June 1 1 , 1991 , incorporated herein by reference). Such patches may be constructed for continuous, pulsatile
  • Controlled release formulations for parenteral administration include liposomal, polymeric microsphere and polymeric gel formulations that are known in the art.
  • a compound of the present invention can be desirable or necessary to introduce a compound of the present invention to the patient via a mechanical delivery device.
  • the construction and use of mechanical delivery devices for the delivery of pharmaceutical agents is well known in the art.
  • Direct techniques for, for example, administering a drug directly to the brain usually involve placement of a drug delivery catheter into the patient's ventricular system to bypass the blood-brain barrier.
  • One such implantable delivery system, used for the transport of agents to specific anatomical regions of the body, is described in US Patent No. 5,01 1 ,472, issued April 30, 1991 .
  • compositions of the invention can also contain other conventional pharmaceutically acceptable compounding ingredients, generally referred to as carriers or diluents, as necessary or desired.
  • Conventional procedures for preparing such compositions in appropriate dosage forms can be utilized. Such ingredients and procedures include those described in the following references, each of which is incorporated herein by reference: Powell, M.F. et al, "Compendium of Excipients for Parenteral Formulations " PDA Journal of Pharmaceutical Science & Technology 1 998, 52(5), 238-31 1 ; Strickley, R.G “Parenteral Formulations of Small Molecule Therapeutics Marketed in the United States (1999)-Part-1 " PDA Journal of Pharmaceutical Science & Technology 1999, 53(6), 324-349; and Nema, S. ef al, "Excipients and Their Use in Injectable Products” PDA Journal of Pharmaceutical Science & Technology 1997, 51 (4), 166-171 .
  • Commonly used pharmaceutical ingredients that can be used as appropriate to formulate the composition for its intended route of administration include: acidifying agents (examples include but are not limited to acetic acid, citric acid, fumaric acid, hydrochloric acid, nitric acid); alkalinizing agents (examples include but are not limited to ammonia solution, ammonium carbonate, diethanolamine, monoethanolamine, potassium hydroxide, sodium borate, sodium carbonate, sodium hydroxide, triethanolamine, trolamine); adsorbents (examples include but are not limited to powdered cellulose and activated charcoal); aerosol propellants (examples include but are not limited to carbon dioxide, CCI2F2, F2CIC-CCIF2 and CCIFs) air displacement agents (examples include but are not limited to nitrogen and argon); antifungal preservatives (examples include but are not limited to benzoic acid, butylparaben, ethylparaben, methylparaben
  • clarifying agents include but are not limited to bentonite
  • emulsifying agents include but are not limited to acacia, cetomacrogol, cetyl alcohol, glyceryl monostearate, lecithin, sorbitan monooleate, polyoxyethylene 50 monostearate
  • encapsulating agents include but are not limited to gelatin and cellulose acetate phthalate
  • flavorants include but are not limited to anise oil, cinnamon oil, cocoa, menthol, orange oil, peppermint oil and vanillin
  • humectants include but are not limited to glycerol, propylene glycol and sorbitol
  • levigating agents include but are not
  • compositions according to the present invention can be illustrated as follows:
  • Sterile IV Solution A 5 mg/mL solution of the desired compound of this invention can be made using sterile, injectable water, and the pH is adjusted if necessary. The solution is diluted for administration to 1 - 2 mg/mL with sterile 5% dextrose and is administered as an IV infusion over about 60 minutes.
  • a sterile preparation can be prepared with (i) 100 - 1000 mg of the desired compound of this invention as a lypholized powder, (ii) 32- 327 mg/mL sodium citrate, and (iii) 300 - 3000 mg Dextran 40.
  • the formulation is reconstituted with sterile, injectable saline or dextrose 5% to a concentration of 10 to 20 mg/mL, which is further diluted with saline or dextrose 5% to 0.2 - 0.4 mg/mL, and is administered either IV bolus or by IV infusion over 15 - 60 minutes.
  • Intramuscular suspension The following solution or suspension can be prepared, for intramuscular injection:
  • Hard Shell Capsules A large number of unit capsules are prepared by filling standard two-piece hard galantine capsules each with 100 mg of powdered active ingredient, 150 mg of lactose, 50 mg of cellulose and 6 mg of magnesium stearate.
  • Soft Gelatin Capsules A mixture of active ingredient in a digestible oil such as soybean oil, cottonseed oil or olive oil is prepared and injected by means of a positive displacement pump into molten gelatin to form soft gelatin capsules containing 1 00 mg of the active ingredient. The capsules are washed and dried. The active ingredient can be dissolved in a mixture of polyethylene glycol, glycerin and sorbitol to prepare a water miscible medicine mix.
  • Tablets A large number of tablets are prepared by conventional procedures so that the dosage unit is 100 mg of active ingredient, 0.2 mg. of colloidal silicon dioxide, 5 mg of magnesium stearate, 275 mg of microcrystalline cellulose, 1 1 mg. of starch, and 98.8 mg of lactose. Appropriate aqueous and non-aqueous coatings may be applied to increase palatability, improve elegance and stability or delay absorption. Immediate Release Tablets/Capsules: These are solid oral dosage forms made by conventional and novel processes. These units are taken orally without water for immediate dissolution and delivery of the medication. The active ingredient is mixed in a liquid containing ingredient such as sugar, gelatin, pectin and sweeteners.
  • a liquid containing ingredient such as sugar, gelatin, pectin and sweeteners.
  • the drug compounds may be compressed with viscoelastic and thermoelastic sugars and polymers or effervescent components to produce porous matrices intended for immediate release, without the need of water.
  • the compounds of formula (I) and the stereoisomers thereof have valuable pharmaceutical properties, which make them commercially utilizable.
  • they inhibit the PI3K/AKT pathway and exhibit cellular activity.
  • They are expected to be commercially applicable in the therapy of diseases (e.g. diseases dependent on overactivated PI3K/AKT).
  • An abnormal activation of the PI3K/AKT pathway is an essential step towards the initiation and maintenance of human tumors and thus its inhibition, for example with PI3K inhibitors, is understood to be a valid approach for treatment of human tumors.
  • PI3K inhibitors for example with PI3K inhibitors, is understood to be a valid approach for treatment of human tumors.
  • the compounds of the present invention can be used for the treatment or prophylaxis of diseases of uncontrolled cell growth, proliferation and/or survival, inappropriate cellular immune responses, or inappropriate cellular inflammatory responses, or diseases which are accompanied with uncontrolled cell growth, proliferation and/or survival, inappropriate cellular immune responses, or inappropriate cellular inflammatory responses, particularly in which the uncontrolled cell growth, proliferation and/or survival, inappropriate cellular immune responses, or inappropriate cellular inflammatory responses, such as, for example, haematological tumours, solid tumours, and/or metastases thereof, e.g.
  • leukaemias and myelodysplastic syndrome including leukaemias and myelodysplastic syndrome, malignant lymphomas, head and neck tumours including brain tumours and brain metastases, tumours of the thorax including non-small cell and small cell lung tumours, gastrointestinal tumours, endocrine tumours, mammary and other gynaecological tumours, urological tumours including renal, bladder and prostate tumours, skin tumours, and sarcomas, and/or metastases thereof.
  • One embodiment relates to the use of a compound of general formula (I) according to any one of claims 1 to 9 for the preparation of a medicament for the treatment or prophylaxis of a cancer, particularly breast cancer, prostate cancer, multiple myeloma, hepatocyte carcinoma, lung cancer, in particular non-small cell lung carcinoma, colorectal cancer, melanoma, pancreatic cancer and/or metastases thereof.
  • a cancer particularly breast cancer, prostate cancer, multiple myeloma, hepatocyte carcinoma, lung cancer, in particular non-small cell lung carcinoma, colorectal cancer, melanoma, pancreatic cancer and/or metastases thereof.
  • the invention relates to the use in the treatment of cancer indications particularly for such cancer types which are known to form metastases in bone.
  • Such cancer types include, but are not limited to, breast, prostate, multiple myeloma, lung, kidney or thyroid cancer.
  • Another embodiment relates to the use of a compound of general formula (I) according to the present invention for the preparation of a medicament for the treatment or prophylaxis of breast cancer or prostate cancer and/or metastases thereof, especially wherein the metastases are bone metastases.
  • Another embodiment relates to the use of a compound of general formula (I) according to the present invention for the preparation of a medicament for the treatment or prophylaxis of breast cancer, multiple myeloma or prostate cancer and/or metastases thereof, especially wherein the metastases are bone metastases.
  • the invention relates to a method of treatment or prophylaxis of a cancer, particularly hepatocyte carcinoma, lung cancer, in particular non- small cell lung carcinoma, colorectal cancer, melanoma, pancreatic cancer, prostate cancer, multiple myeloma, breast cancer and/or metastases thereof, in a subject, comprising administering to said subject a therapeutically effective amount of a compound according to any one of claims 1 to 9.
  • Another embodiment relates to a compound of general formula (I) according to the present invention for use in the treatment of a cancer, particularly hepatocyte carcinoma, lung cancer, in particular non-small cell lung carcinoma, colorectal cancer, melanoma, pancreatic cancer, prostate cancer, multiple myeloma, breast cancer and/or metastases thereof, more particularly breast cancer, multiple myeloma or prostate cancer and/or metastases thereof, especially wherein the metastases are bone metastases.
  • a cancer particularly hepatocyte carcinoma, lung cancer, in particular non-small cell lung carcinoma, colorectal cancer, melanoma, pancreatic cancer, prostate cancer, multiple myeloma, breast cancer and/or metastases thereof, more particularly breast cancer, multiple myeloma or prostate cancer and/or metastases thereof, especially wherein the metastases are bone metastases.
  • Preferred uses of the compounds of the invention are the treatment of breast and prostate cancer, especially castration-resistant prostate cancer (CRPC), and bone metastases thereof.
  • CRPC castration-resistant prostate cancer
  • One preferred embodiment is the use of the compounds of the invention for the treatment of prostate cancer, especially castration-resistant prostate cancer (CRPC) and bone metastases thereof.
  • CRPC castration-resistant prostate cancer
  • One preferred embodiment is the use of the compounds of the invention for the treatment of breast cancer and bone metastases thereof.
  • One preferred embodiment is the use of the compounds of the invention for the treatment of multiple myeloma and bone metastases thereof.
  • inappropriate within the context of the present invention, in particular in the context of "inappropriate cellular immune responses, or inappropriate cellular inflammatory responses", as used herein, is to be understood as preferably meaning a response which is less than, or greater than normal, and which is associated with, responsible for, or results in, the pathology of said diseases.
  • Compounds of the present invention might be utilized to inhibit, block, reduce, decrease, etc., cell proliferation and/or cell division, and/or produce apoptosis.
  • This invention includes a method comprising administering to a mammal in need thereof, including a human, an amount of a compound of this invention, or a pharmaceutically acceptable salt, isomer, polymorph, metabolite, hydrate, solvate or ester thereof ; etc. which is effective to treat the disorder.
  • Hyper-proliferative disorders include but are not limited, e.g., psoriasis, keloids, and other hyperplasias affecting the skin, benign prostate hyperplasia (BPH), as well as malignant neoplasia.
  • BPH benign prostate hyperplasia
  • malignant neoplasia treatable with the compounds according to the present invention include solid and hematological tumors. Solid tumors can be exemplified by tumors of the breast, bladder, bone, brain, central and peripheral nervous system, colon, anum, endocrine glands (e.g.
  • malignant neoplasias include inherited cancers exemplified by Retinoblastoma and Wilms tumor. In addition, malignant neoplasias include primary tumors in said organs and corresponding secondary tumors in distant organs ("tumor metastases").
  • Hematological tumors can be exemplified by aggressive and indolent forms of leukemia and lymphoma, namely non-Hodgkins disease, chronic and acute myeloid leukemia (CML / AML), acute lymphoblastic leukemia (ALL), Hodgkins disease, multiple myeloma and T-cell lymphoma. Also included are myelodysplastic syndrome, plasma cell neoplasia, paraneoplastic syndromes, and cancers of unknown primary site as well as AIDS related malignancies.
  • breast cancer examples include, but are not limited to invasive ductal carcinoma, invasive lobular carcinoma, ductal carcinoma in situ, and lobular carcinoma in situ.
  • cancers of the respiratory tract include, but are not limited to small- cell and non-small-cell lung carcinoma, as well as bronchial adenoma and pleuropulmonary blastoma.
  • brain cancers include, but are not limited to brain stem and hypophtalmic glioma, cerebellar and cerebral astrocytoma, medulloblastoma, ependymoma, as well as neuroectodermal and pineal tumor.
  • Tumors of the male reproductive organs include, but are not limited to prostate and testicular cancer.
  • Tumors of the female reproductive organs include, but are not limited to endometrial, cervical, ovarian, vaginal, and vulvar cancer, as well as sarcoma of the uterus.
  • Tumors of the digestive tract include, but are not limited to anal, colon, colorectal, esophageal, gallbladder, gastric, pancreatic, rectal, small-intestine, and salivary gland cancers.
  • Tumors of the urinary tract include, but are not limited to bladder, penile, kidney, renal pelvis, ureter, urethral and human papillary renal cancers.
  • Eye cancers include, but are not limited to intraocular melanoma and retinoblastoma.
  • liver cancers include, but are not limited to hepatocellular carcinoma (liver cell carcinomas with or without fibrolamellar variant), cholangiocarcinoma (intrahepatic bile duct carcinoma), and mixed hepatocellular cholangiocarcinoma.
  • Skin cancers include, but are not limited to squamous cell carcinoma, Kaposi's sarcoma, malignant melanoma, Merkel cell skin cancer, and non-melanoma skin cancer.
  • Head-and-neck cancers include, but are not limited to laryngeal, hypopharyngeal, nasopharyngeal, oropharyngeal cancer, lip and oral cavity cancer and squamous cell.
  • Lymphomas include, but are not limited to AIDS- related lymphoma, non-Hodgkin's lymphoma, cutaneous T-cell lymphoma, Burkitt lymphoma, Hodgkin's disease, and lymphoma of the central nervous system.
  • Sarcomas include, but are not limited to sarcoma of the soft tissue, osteosarcoma, malignant fibrous histiocytoma, lymphosarcoma, and rhabdomyosarcoma.
  • Leukemias include, but are not limited to acute myeloid leukemia, acute lymphoblastic leukemia, chronic lymphocytic leukemia, chronic myelogenous leukemia, and hairy cell leukemia.
  • treating or “treatment” as stated throughout this document is used conventionally, e.g., the management or care of a subject for the purpose of combating, alleviating, reducing, relieving, improving the condition of, etc., of a disease or disorder, such as a carcinoma.
  • Compounds of the present invention might also be used for treating disorders and diseases associated with excessive and/or abnormal angiogenesis.
  • Inappropriate and ectopic expression of angiogenesis can be deleterious to an organism.
  • a number of pathological conditions are associated with the growth of extraneous blood vessels. These include, e.g., diabetic retinopathy, ischemic retinal-vein occlusion, and retinopathy of prematurity [Aiello et al. New Engl. J. Med. 1994, 331 , 1480 ; Peer et al. Lab. Invest. 1995, 72, 638], age-related macular degeneration [AMD ; see, Lopez et al. Invest. Opththalmol. Vis. Sci.
  • neovascular glaucoma neovascular glaucoma, psoriasis, retrolental fibroplasias, angiofibroma, inflammation, rheumatoid arthritis (RA), restenosis, in-stent restenosis, vascular graft restenosis, etc.
  • RA rheumatoid arthritis
  • restenosis in-stent restenosis
  • vascular graft restenosis etc.
  • the increased blood supply associated with cancerous and neoplastic tissue encourages growth, leading to rapid tumor enlargement and metastasis.
  • the growth of new blood and lymph vessels in a tumor provides an escape route for renegade cells, encouraging metastasis and the consequence spread of the cancer.
  • combinations of the present invention can be utilized to treat and/or prevent any of the aforementioned angiogenesis disorders, e.g., by inhibiting and/or reducing blood vessel formation ; by inhibiting, blocking, reducing, decreasing, etc. endothelial cell proliferation or other types involved in angiogenesis, as well as causing cell death or apoptosis of such cell types.
  • the effective dosage of the compounds of this invention can readily be determined for treatment of each desired indication.
  • the amount of the active ingredients to be administered in the treatment of one of these conditions can vary widely according to such considerations as the particular compound and dosage unit employed, the mode of administration, the period of treatment, the age and sex of the patient treated, and the nature and extent of the condition treated.
  • the total amount of the active ingredients to be administered will generally range from about 0.001 mg/kg to about 200 mg/kg body weight per day, and preferably from about 0.01 mg/kg to about 20 mg/kg body weight per day.
  • Clinically useful dosing schedules of a compound will range from one to three times a day dosing to once every four weeks dosing.
  • "drug holidays" in which a patient is not dosed with a drug for a certain period of time may be beneficial to the overall balance between pharmacological effect and tolerability.
  • a unit dosage may contain from about 0.5 mg to about 1 500 mg of active ingredient, and can be administered one or more times per day or less than once a day.
  • the average daily dosage for administration by injection will preferably be from 0.01 to 200 mg/kg of total body weight.
  • the average daily rectal dosage regimen will preferably be from 0.01 to 200 mg/kg of total body weight.
  • the average daily vaginal dosage regimen will preferably be from 0.01 to 200 mg/kg of total body weight.
  • the average daily topical dosage regimen will preferably be from 0.1 to 200 mg administered between one to four times daily.
  • the transdermal concentration will preferably be that required to maintain a daily dose of from 0.01 to 200 mg/kg.
  • the average daily inhalation dosage regimen will preferably be from 0.01 to 100 mg/kg of total body weight.
  • the combinations of the present invention can be used in particular in therapy and prevention, i.e. prophylaxis, of tumour growth and metastases, especially in solid tumours of all indications and stages with or without pre-treatment of the tumour growth, more especially those tumor types spreading into bones.
  • the compounds of this invention can be administered as the sole pharmaceutical agent or in combination with one or more further pharmaceutical agents where the resulting combination of compounds causes no unacceptable adverse effects.
  • the compounds of this invention can be combined with one or more further pharmaceutical agents, such as known anti- angiogenesis, anti-hyper-proliferative, antiinflammatory, analgesic, immunoregulatory, diuretic, antiarrhytmic, anti-hypercholsterolemia, anti- dyslipidemia, anti-diabetic or antiviral agents, and the like, as well as with admixtures and combinations thereof.
  • the one or more further pharmaceutical agents are selected from anti-angiogenesis, anti-hyper-proliferative and/or admixtures or combinations thereof.
  • the one or more further pharmaceutical agents are selected from antiinflammatory, analgesic, immunoregulatory, diuretic, antiarrhytmic, anti- hypercholsterolemia, anti-dyslipidemia, anti-diabetic or antiviral agents, and/or admixtures or combinations thereof.
  • Further pharmaceutical agents can be one or more pharmaceutical agents such as 131 1-chTNT, abarelix, abiraterone, aclarubicin, aldesleukin, alemtuzumab, alitretinoin, altretamine, aminoglutethimide, amrubicin, amsacrine, anastrozole, arglabin, arsenic trioxide, asparaginase, azacitidine, basiliximab, belotecan, bendamustine, bevacizumab, bexarotene, bicalutamide, bisantrene, bleomycin, bortezomib, buserelin, busulfan, cabazitaxel, calcium folinate, calcium levofolinate, capecitabine, carboplatin, carmofur, carmustine, catumaxomab, celecoxib, celmoleukin, cetuximab, chlorambucil, chlormadinone,
  • said further pharmaceutical agents can be one or more further pharmaceutical agents selected from gemcitabine, paclitaxel, cisplatin, carboplatin, sodium butyrate, 5-FU, doxirubicin, tamoxifen, etoposide, trastumazab, gefitinib, intron A, rapamycin, 17-AAG, U0126, insulin, an insulin derivative, a PPAR ligand, a sulfonylurea drug, an a-glucosidase inhibitor, a biguanide, a PTP-1 B inhibitor, a DPP-IV inhibitor, a 1 1 -beta-HSD inhibitor, GLP- 1 , a GLP-1 derivative, GIP, a GIP derivative, PACAP, a PACAP derivative, secretin or a secretin derivative.
  • further pharmaceutical agents selected from gemcitabine, paclitaxel, cisplatin, carboplatin, sodium butyrate, 5-FU, doxirubicin,
  • Optional anti-hyper-proliferative agents which can be added as further pharmaceutical agents to the compounds of the present invention include but are not limited to compounds listed on the cancer chemotherapy drug regimens in the 1 1 th Edition of the Merck Index, (1996), which is hereby incorporated by reference, such as asparaginase, bleomycin, carboplatin, carmustine, chlorambucil, cisplatin, colaspase, cyclophosphamide, cytarabine, dacarbazine, dactinomycin, daunorubicin, doxorubicin (adriamycine), epirubicin, etoposide, 5- fluorouracil, hexamethylmelamine, hydroxyurea, ifosfamide, irinotecan, leucovorin, lomustine, mechlorethamine, 6-mercaptopurine, mesna, methotrexate, mitomycin C, mitoxantrone, predn
  • anti-hyper-proliferative agents suitable for use further pharmaceutical agents with the compounds the present invention include but are not limited to those compounds acknowledged to be used in the treatment of neoplastic diseases in Goodman and Gilman's The Pharmacological Basis of Therapeutics (Ninth Edition), editor Molinoff et al., publ.
  • anti-hyper-proliferative agents suitable for use as further pharmaceutical agents with the compounds of the present invention include but are not limited to other anti-cancer agents such as epothilone and its derivatives, irinotecan, raloxifen and topotecan.
  • cytotoxic and/or cytostatic agents as further pharmaceutical agents in combination with a compound of the present invention will serve to: yield better efficacy in reducing the growth of a tumor and/or metastasis or even eliminate the tumor and/ or metastasis as compared to administration of either agent alone, provide for the administration of lesser amounts of the administered chemotherapeutic agents, provide for a chemotherapeutic treatment that is well tolerated in the patient with fewer deleterious pharmacological complications than observed with single agent chemotherapies and certain other combined therapies, provide for treating a broader spectrum of different cancer types in mammals, especially humans, provide for a higher response rate among treated patients, provide for a longer survival time among treated patients compared to standard chemotherapy treatments, provide a longer time for tumor progression, and/or yield efficacy and tolerability results at least as good as those of the agents used alone, compared to known instances where other cancer agent combinations produce antagonistic effects.
  • Compound A1 is a PI3K inhibitor as disclosed in the experimental section of WO2012/062748 in example 14 (N-(8- ⁇ [(2R)-2-hydroxy-3-(morpholin-4- yl)propyl]oxy ⁇ -7-methoxy-2,3-dihydroimidazo[1 ,2-c]quinazolin-5-yl)-2- meth lpyridine-3-carboxamide).
  • the monotherapy of compound A1 was tested in a syngeneic animal model that resembles the characteristics of breast cancer bone metastatic disease in humans. This model can be effectively used for testing the effects of cancer drug candidates on the metastasis of breast cancer cells to bone.
  • the osteolytic lesions and whole body tumor burden were measured by x-ray and fluorescence imaging at sacrifice. Furthermore, tissue samples from the left and right tibia and femur were collected for further histomorphometric analysis. Tissue was embedded in paraffin for histomorphometric analysis of bone and tumor area.
  • the effects of PI3K inhibitor Compound A1 in MCF-7 and 4T1 breast cancer cells and PC-3 and LNCaP prostate cancer cells were investigated in vitro. The effects were studied by measuring cell proliferation and apoptosis. The PI3K inhibitor(s) was added at day -1 and at day 4. The following two concentrations of the inhibitors were tested:
  • the effects on cell proliferation were studied using a WST-1 based proliferation assay and the effects on apoptosis were studied in parallel plates by measuring caspase 3/7 activity. The measurements were performed at 4 different time points, days 1 , 2, 3 and 5. Caspase activity was normalized to the cell number obtained with the WST-1 assay in parallel plates.
  • the reference compound doxorubicin inhibited proliferation in all tested cell lines; MCF-7, 4T1 , PC-3 and LNCaP, describing that the assays were performed successfully and the results obtained are reliable.
  • the following seven multiple myeloma cell lines are tested: 5TGM1 , JJN3, LP-1 , L363, MOLP-8, RPMI8226, OPM-2.
  • the effects of Ra-223 and PI3K inhibitor compound A1 and their combinations on proliferation and apoptosis of the multiple myeloma cell lines are studied. Proliferation is measured using WST-1 based proliferation assay and apoptosis by measuring caspase 3/7 activity.
  • the following groups are tested for each of the 7 cell lines in both the WST-1 and caspase 3/7 measurements:
  • Test group receiving dose 2 of PI3Ki Compound A1 A benefitial therapeutic effect is observed with the use of the PI3Ki compound A1 .
  • Figure 2 Total osteolytic area at sacrifice (mm2, median ⁇ IQR25% ⁇ min /max).
  • Control group received vehicle and PI3K group was given 75 mg/kg of Compound A1 and vehicle.
  • Figure 3 Mean osteolytic area at sacrifice (mm2, median ⁇ IQR25% ⁇ min /max).
  • Treatment with PI3K inhibitor Compound A1 showed trend of decreasing the mean osteolytic area. Statistical significance could not be reached likely due to the short treatment time (aggressive model with average survival of 5.7 days in the vehicle group) and a small sample number.
  • Control group received vehicle and PI3Ki group was given 75 mg/kg of Compound A1 and vehicle.
  • Figure 4 Relative tumor area in bone marrow area. Trends of inhibition of tumor cells in bone marrow area by PI3Ki Compound A1 . Statistical significance could not be reached likely due to the short treatment time (aggressive model with average survival of 5.7 days in the vehicle group) and a small sample number.
  • Control group received vehicle and PI3Ki group was given 75 mg/kg of Compound A1 and vehicle.
  • Control group received vehicle and PI3Ki group was given 75 mg/kg of Compound A1 and vehicle.
  • Figure 15 Inhibition of the number of osteoblasts by Compound A1.
  • the number of osteoblasts were counted from MGT -stained sections based on morphology and location. Two microscope fields at 1 0x magnification were analyzed. The number of osteoblasts was reduced with the treatment of compound A1 .
  • Compound A1 showed potent anti-proliferative activity and at high dose induced tumor cell apoptosis.
  • Compound A1 demonstrated direct anti-tumor activity in all 4 breast and prostate tumor cell lines tested, and induced tumor cell death in hormone receptor positive MCF7 (ER+) breast cancer and LNCaP (AR+) prostate tumor cell lines.
  • ER+ hormone receptor positive MCF7
  • AR+ LNCaP
  • the TSC1 -2 tumor suppressor controls insulin-PI3K signaling via regulation of IRS proteins. J. Cell Biol. 2004, 766, 213-223. 16. Barone, I.; Cui, Y.; Herynk, M. H.; Corona- Rodriguez, A.; Giordano, C; Selever, J.; Beyer, A.; Ando, S.; Fuqua, S. A. W. Expression of the K303R estrogen receptor-a breast cancer mutation induces resistance to an aromatase inhibitor via addiction to the PI3K/Akt kinase pathway. Cancer Res. 2009, 69, 4724-4732. 17. Jozwiak, J.; Jozwiak, S.; Wlodarski, P. Possible mechanisms of disease development in tuberous sclerosis. Lancet Oncol. 2008, 9, 73-79.

Abstract

La présente invention concerne des inhibiteurs de kinase PI3K pour le traitement ou la prophylaxie d'une maladie, notamment le traitement de cancers ou de leurs métastases.
PCT/EP2014/076051 2013-12-03 2014-12-01 Utilisation d'inhibiteurs de pi3k WO2015082376A2 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP13195567.6 2013-12-03
EP13195567 2013-12-03
EP14163752 2014-04-07
EP14163752.0 2014-04-07

Publications (2)

Publication Number Publication Date
WO2015082376A2 true WO2015082376A2 (fr) 2015-06-11
WO2015082376A3 WO2015082376A3 (fr) 2015-07-30

Family

ID=51999440

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2014/076051 WO2015082376A2 (fr) 2013-12-03 2014-12-01 Utilisation d'inhibiteurs de pi3k

Country Status (1)

Country Link
WO (1) WO2015082376A2 (fr)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017079746A2 (fr) 2015-11-07 2017-05-11 Multivir Inc. Méthodes et compositions comprenant une thérapie génique suppressive de tumeur et le blocage du point de contrôle immunitaire pour le traitement du cancer
WO2018111902A1 (fr) 2016-12-12 2018-06-21 Multivir Inc. Méthodes et compositions comprenant une thérapie génique virale et un inhibiteur de point de contrôle immunitaire pour le traitement et la prévention du cancer et des maladies infectieuses
WO2020036635A2 (fr) 2018-03-19 2020-02-20 Multivir Inc. Procédés et compositions comprenant une thérapie génique suppressive de tumeur et des agonistes de cd122/cd132 pour le traitement du cancer
US10933052B2 (en) 2017-11-17 2021-03-02 Cellix Bio Private Limited Compositions and methods for the treatment of eye disorders
WO2021113644A1 (fr) 2019-12-05 2021-06-10 Multivir Inc. Combinaisons comprenant un activateur de lymphocytes t cd8+, un inhibiteur de point de contrôle immunitaire et une radiothérapie en vue d'obtenir des effets ciblés et abscopal pour le traitement du cancer

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5011472A (en) 1988-09-06 1991-04-30 Brown University Research Foundation Implantable delivery system for biological factors
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
WO2012062748A1 (fr) 2010-11-11 2012-05-18 Bayer Pharma Aktiengesellschaft Dérivés de 2,3-dihydroimidazo[1,2-c]quinazoléine substitués par un aminoalcool utiles pour traiter des troubles hyperprolifératifs et des maladies associées à l'angiogenèse

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2168583A1 (fr) * 2008-09-24 2010-03-31 Bayer Schering Pharma Aktiengesellschaft Utilisation de 2,3-dihydroimidazo[1,2-c]quinazolines substituées pour le traitement du myélome
EA201201414A8 (ru) * 2010-04-16 2013-12-30 Байер Интеллектчуал Проперти Гмбх КОМБИНАЦИИ, СОДЕРЖАЩИЕ ЗАМЕЩЕННЫЕ 2,3-ДИГИДРОИМИДАЗО[1,2-c]ХИНАЗОЛИНЫ
US9675616B2 (en) * 2010-11-11 2017-06-13 Bayer Intellectual Property Gmbh Arylaminoalcohol-substituted 2,3-dihydroimidazo[1,2-C]quinolines
JO3733B1 (ar) * 2011-04-05 2021-01-31 Bayer Ip Gmbh استخدام 3,2-دايهيدروايميدازو[1, 2 -c]كوينازولينات مستبدلة
CU24400B1 (es) * 2013-04-08 2019-04-04 Bayer Pharma AG Una composición que comprende 2,3-dihidroimidazo[1,2-c]quinazolinas sustituidas

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5011472A (en) 1988-09-06 1991-04-30 Brown University Research Foundation Implantable delivery system for biological factors
WO2012062748A1 (fr) 2010-11-11 2012-05-18 Bayer Pharma Aktiengesellschaft Dérivés de 2,3-dihydroimidazo[1,2-c]quinazoléine substitués par un aminoalcool utiles pour traiter des troubles hyperprolifératifs et des maladies associées à l'angiogenèse

Non-Patent Citations (47)

* Cited by examiner, † Cited by third party
Title
"Goodman and Gilman's The Pharmacological Basis of Therapeutics", 1996, MCGRAW-HILL, pages: 1225 - 1287
"Merck Index", 1996
AIELLO ET AL., NEW ENGL. J. MED., vol. 331, 1994, pages 1480
ALESSI, D. R.; PEARCE, L. R.; GARCIA-MARTINEZ, J. M.: "New insights into mTOR signaling: mTORC2 and beyond", SCI. SIGNAL., vol. 2, 2009, pages E27
BARONE, I.; CUI, Y.; HERYNK, M. H.; CORONA-RODRIGUEZ, A.; GIORDANO, C.; SELEVER, J.; BEYER, A.; ANDO, S.; FUQUA, S. A. W.: "Expression of the K303R estrogen receptor-a breast cancer mutation induces resistance to an aromatase inhibitor via addiction to the P13K/Akt kinase pathway", CANCER RES., vol. 69, 2009, pages 4724 - 4732
BENISTANT, C.; CHAPUIS, H.; ROCHE, S.: "A specific function for phosphatidylinositol 3-kinase a (p85a-p110a) in cell survival and for phosphatidylinositol 3-kinase b (p85a-p110b) in de novo DNA synthesis of human colon carcinoma cells", ONCOGENE, vol. 19, 2000, pages 5083 - 5090
BRUGGE, J.; HUNG, M.-C.; MILLS, G. B.: "A new mutational aktivation in the P13K pathway", CANCER CELL, vol. 12, 2007, pages 104 - 107
BRULAND O. S.; NILSSON S.; FISHER D.R. ET AL.: "High-linear energy transfer irradiation targeted to skeletal metastases by the alpha-emitter Ra: adjuvant or alternative to conventional modalities?", CLIN. CANCER RES., vol. 12, 2006, pages 6250S - 7S
BYUN, D.-S.; CHO, K.; RYU, B.-K.; LEE, M.-G.; PARK, J.-I.; CHAE, K.-S.; KIM, H.-J.; CHI, S.-G.: "Frequent monoallelic deletion of PTEN and its reciprocal association with PIK3CA amplification in gastric carcinoma", INT. J. CANCER, vol. 104, 2003, pages 318 - 327
DATTA, S. R.; DUDEK, H.; TAO, X.; MASTERS, S.; FU, H.; GOTOH, Y.; GREENBERG, M. E.: "Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery", CELL, vol. 91, 1997, pages 231 - 241
GARCIA-ECHEVERRIA ET AL., ONCOGENE, vol. 27, 2008, pages 551 - 5526
HARRINGTON, L. S.; FINDLAY, G. M.; GRAY, A.; TOLKACHEVA, T.; WIGFIELD, S.; REBHOLZ, H.; BARNETT, J.; LESLIE, N. R.; CHENG, S.; SHE: "The TSC1 -2 tumor suppressor controls insulin-P13K signaling via regulation of IRS proteins", J. CELL BIOL., vol. 166, 2004, pages 213 - 223
JIA, S.; LIU, Z.; ZHANG, S.; LIU, P.; ZHANG, L.; LEE, S. H.; ZHANG, J.; SIGNORETTI, S.; LODA, M.; ROBERTS, T. M.: "Essential roles of PI(3)K-p110b in cell growth, metabolism and tumorigenesis", NATURE, vol. 454, 2008, pages 776 - 779
JIA, S.; ROBERTS, T. M.; ZHAO, J. J.: "Should individual P13 kinase isoforms be targeted in cancer?", CURR. OPIN. CELL BIOL., vol. 21, 2009, pages 199 - 208
JOZWIAK, J.; JOZWIAK, S.; WLODARSKI, P.: "Possible mechanisms of disease development in tuberous sclerosis", LANCET ONCOL., vol. 9, 2008, pages 73 - 79
LEE, S. H.; POULOGIANNIS, G.; PYNE, S.; JIA, S; ZOU, L.; SIGNORETTI, S.; LODA, M.; CANTLEY, L. C.; ROBERTS, T. M.: "A constitutively activated form of the p110b isoform of P13-kinase induces prostatic intraepithelial neoplasia in mice", PROC. NATL. ACAD. SCI. U. S. A., vol. 107, no. 11002-, 2010, pages S11002,11001 - S11002,11050
LI, Y.-L.; TIAN, Z.; WU, D.-Y.; FU, B.-Y.; XIN, Y.: "Loss of heterozygosity on 10q23.3 and mutation of tumor suppressor gene PTEN in gastric cancer and precancerous lesions", WORLD J. GASTROENTEROL., vol. 11, 2005, pages 285 - 288
LIU, P.; CHENG, H.; ROBERTS, T. M.; ZHAO, J. J.: "Targeting the phosphoinositide 3-kinase pathway in cancer", NAT. REV. DRUG DISC., vol. 8, 2009, pages 627 - 644
LOPEZ ET AL., INVEST. OPTHTHALMOL. VIS. SCI., vol. 37, 1996, pages 855
MANNING, B. D.; CANTLEY, L. C.: "AKT/PKB signaling: navigating downstream", CELL, vol. 129, 2007, pages 1261 - 1274
MARONE, R.; CMILJANOVIC, V.; GIESE, B.; WYMANN, M. P.: "Targeting phosphoinositide 3-kinase - moving towards therapy", BIOCHIM. BIOPHYS. ACTA, PROTEINS PROTEOMICS, vol. 1784, 2008, pages 159 - 185
MARQUES, M.; KUMAR, A.; POVEDA, A. M.; ZULUAGA, S.; HERNANDEZ, C.; JACKSON, S.; PASERO, P.; CARRERA, A. C.: "Specific function of phosphoinositide 3-kinase beta in the control of DNA replication", PROC. NATL. ACAD. SCI. U. S. A., vol. 106, 2009, pages 7525 - 7530
NEMA, S. ET AL.: "Excipients and Their Use in Injectable Products", PDA JOURNAL OF PHARMACEUTICAL SCIENCE & TECHNOLOGY, vol. 51, no. 4, 1997, pages 166 - 171
NICHOLSON, K. M.; ANDERSON, N. G.: "The protein kinase B/Akt signalling pathway in human malignancy", CELL. SIGNALLING, vol. 14, 2002, pages 381 - 395
OBENAUER, J. C.; CANTLEY, L. C.; YAFFE, M. B.: "Scansite 2.0: proteome-wide prediction of cell signaling interactions using short sequence motifs", NUCLEIC ACIDS RES., vol. 31, 2003, pages 3635 - 3641
OKI, E.; KAKEJI, Y.; BABA, H.; TOKUNAGA, E.; NAKAMURA, T.; UEDA, N.; FUTATSUGI, M.; YAMAMOTO, M.; IKEBE, M.; MAEHARA, Y.: "Impact of loss of heterozygosity of encoding phosphate and tensin homolog on the prognosis of gastric cancer", J. GASTROENTEROL. HEPATOL., vol. 21, 2006, pages 814 - 818
OKUMURA, E.; FUKUHARA, T.; YOSHIDA, H.; HANADA, S.; KOZUTSUMI, R.; MORI, M.; TACHIBANA, K.; KISHIMOTO, T.: "Akt inhibits Myt1 in the signalling pathway that leads to meiotic G2/M-phase transition", NAT. CELL BIOL., vol. 4, 2002, pages 111 - 116
PEARCE, L. R.; KOMANDER, D.; ALESSI, D. R.: "The nuts and bolts of AGC protein kinases", NAT. REV. MOL. CELL BIOL., vol. 11, 2010, pages 9 - 22
PEER ET AL., LAB. INVEST., vol. 72, 1995, pages 638
POWELL, M.F. ET AL.: "Compendium of Excipients for Parenteral Formulations", PDA JOURNAL OF PHARMACEUTICAL SCIENCE & TECHNOLOGY, vol. 52, no. 5, 1998, pages 238 - 311
PURE APPL CHEM, vol. 45, 1976, pages 11 - 30
ROMASHKOVA, J. A.; MAKAROV, S. S.: "Nf-kB is a target of Akt in anti-apoptotic PDGF signalling", NATURE, vol. 401, 1999, pages 86 - 90
S. M. BERGE ET AL.: "Pharmaceutical Salts", J. PHARM. SCI., vol. 66, 1977, pages 1 - 19
SARBASSOV, D. D.; GUERTIN, D. A.; ALI, S. M.; SABATINI, D. M.: "Phosphorylation and Regulation of Akt/PKB by the Rictor-mTOR Complex", SCIENCE, vol. 307, 2005, pages 1098 - 1101
STRICKLEY, R.G: "Parenteral Formulations of Small Molecule Therapeutics Marketed in the United States (1999)-Part-1", PDA JOURNAL OF PHARMACEUTICAL SCIENCE & TECHNOLOGY, vol. 53, no. 6, 1999, pages 324 - 349
SUJOBERT, P.; BARDET, V.; CORNILLET-LEFEBVRE, P.; HAYFLICK, J. S.; PRIE, N.; VERDIER, F; VANHAESEBROECK, B.; MULLER, 0.; PESCE, F.: "Essential role for the p110d isoform in phosphoinositide 3-kinase activation and cell proliferation in acute myeloid leukemia", BLOOD, vol. 106, 2005, pages 1063 - 1066
TANNOCK, . F.; DE WIT, R.; BERRY, W. R.; HORTI, J.; PLUZANSKA, A.; CHI, K. N.; OUDARD, S.; THEODORE, C.; JAMES, N. D.; TURESSON, I: "Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer", N. ENGL. J. MED., vol. 351, 2004, pages 1502 - 1512
TRAN, H.; BRUNET, A.; GRENIER, J. M.; DATTA, S. R.; FORNACE, A. J., JR.; DISTEFANO, P. S.; CHIANG, L. W.; GREENBERG, M. E.: "DNA repair pathway stimulated by the Forkhead Transcription Factor FOX03a through the Gadd45 protein", SCIENCE, vol. 296, 2002, pages 530 - 534
VANHAESEBROECK, B.; GUILLERMET-GUIBERT, J.; GRAUPERA, M.; BILANGES, B.: "The emerging mechanisms of isoform-specific P13K signaling", NAT. REV. MOL. CELL BIOL., vol. 11, 2010, pages 329 - 341
VASUDEVAN, K. M; BARBIE, D. A.; DAVIES, M. A.; RABINOVSKY, R.; MCNEAR, C. J.; KIM, J. J.; HENNESSY, B. T.; TSENG, H.; POCHANARD, P: "AKT-independent signaling downstream of oncogenic PIK3CA mutations in human cancer", CANCER CELL, vol. 16, 2009, pages 21 - 32
VOGT, P. K.; GYMNOPOULOS, M.; HART, J. R.: "PI 3-kinase and cancer: changing accents", CURR. OPIN. GENET. DEV., vol. 19, 2009, pages 12 - 17
WEE, S.; WIEDERSCHAIN, D.; MAIRA, S.-M.; LOO, A; MILLER, C.; DE BEAUMONT, R.; STEGMEIER, F.; YAO, Y.-M.; LENGAUER, C.: "PTEN-deficient cancers depend on PIK3CB", PROC. NATL. ACAD. SCI. U. S. A., vol. 105, 2008, pages 13057 - 13062
YANG, Q.; GUAN, K.-L.: "Expanding mTOR signaling", CELL RES., vol. 17, 2007, pages 666 - 681
YUAN, T. L.; CANTLEY, L. C.: "P13K pathway alterations in cancer: variations on a theme", ONCOGENE, vol. 27, 2008, pages 5497 - 5510
ZHA, J.; HARADA, H.; YANG, E.; JOCKEL, J.; KORSMEYER, S. J.: "Serine phosphorylation of death agonist BAD in response to survival factor results in binding to 14-3-3 not BCL-XL", CELL, vol. 87, 1996, pages 619 - 628
ZHAO, J. J.; CHENG, H.; JIA, S.; WANG, L.; GJOERUP, O. V.; MIKAMI, A.; ROBERTS, T. M.: "The p110a isoform of P13K is essential for proper growth factor signaling and oncogenic transformation", PROC. NATL. ACAD. SCI. U. S. A., vol. 103, 2006, pages 16296 - 16300
ZHOU, B. P.; LIAO, Y.; XIA, W.; SPOHN, B.; LEE, M.-H.; HUNG, M.-C.: "Cytoplasmic localization of p21 Cip1 /WAF1 by Akt-induced phosphorylation in HER-2/neu-overexpressing cells", NAT. CELL BIOL., vol. 3, 2001, pages 245 - 252

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017079746A2 (fr) 2015-11-07 2017-05-11 Multivir Inc. Méthodes et compositions comprenant une thérapie génique suppressive de tumeur et le blocage du point de contrôle immunitaire pour le traitement du cancer
WO2018111902A1 (fr) 2016-12-12 2018-06-21 Multivir Inc. Méthodes et compositions comprenant une thérapie génique virale et un inhibiteur de point de contrôle immunitaire pour le traitement et la prévention du cancer et des maladies infectieuses
US10933052B2 (en) 2017-11-17 2021-03-02 Cellix Bio Private Limited Compositions and methods for the treatment of eye disorders
WO2020036635A2 (fr) 2018-03-19 2020-02-20 Multivir Inc. Procédés et compositions comprenant une thérapie génique suppressive de tumeur et des agonistes de cd122/cd132 pour le traitement du cancer
WO2021113644A1 (fr) 2019-12-05 2021-06-10 Multivir Inc. Combinaisons comprenant un activateur de lymphocytes t cd8+, un inhibiteur de point de contrôle immunitaire et une radiothérapie en vue d'obtenir des effets ciblés et abscopal pour le traitement du cancer

Also Published As

Publication number Publication date
WO2015082376A3 (fr) 2015-07-30

Similar Documents

Publication Publication Date Title
US10117874B2 (en) Combination of PI3K-inhibitors
EP2897957B1 (fr) Pyrrolopyrimidinylaminobenzothiazolones substituées comme inhibiteurs de mknk kinase
US9777004B2 (en) Amino-substituted imidazopyridazines
EP3268490B1 (fr) Combinaisons contenant des 2,3-dihydroimidazo[1,2-c]quinazoline substituées
EP2852595B1 (fr) Benzothienopyrimidines substituées
CA2837630A1 (fr) Aminoimidazopyridazines substituees
WO2014118226A1 (fr) Pyrazolopyrimidinylaminoindazoles substitués
WO2015082376A2 (fr) Utilisation d'inhibiteurs de pi3k
WO2016087490A1 (fr) Combinaison d'inhibiteurs de la voie pi3k
JP2022177113A (ja) Ｐｉ３ｋ－阻害剤の組み合わせ
WO2018206547A1 (fr) Combinaison d'inhibiteurs de bub1 et d'atr
US10124007B2 (en) Combination of PI3K-inhibitors
WO2015113927A1 (fr) Isothiazoles amino-substitués
US20170217946A1 (en) Amino-substituted isoxazoles
WO2018215282A1 (fr) Combinaison d'inhibiteurs de bub1 et de pi3k
WO2017157418A1 (fr) Combinaison d'inhibiteurs de mknk1
US11185549B2 (en) Combination of a PI3K-inhibitor with an androgen receptor antagonist
TW201417816A (zh) Ａｋｔ抑制劑組合
EP2977375A1 (fr) Isoxazoles substitués par amino
EP2977376A1 (fr) Isoxazoles substitués par amino
EP2977377A1 (fr) Isoxazoles substitués par amino

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14805293

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 14805293

Country of ref document: EP

Kind code of ref document: A2